**NQF #0627 Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent**

**NATIONAL QUALITY FORUM**

*Measure Submission and Evaluation Worksheet 5.0*

This form contains the information submitted by measure developers/stewards, organized according to NQF’s measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the submitting standards web page.

<table>
<thead>
<tr>
<th>NQF #: 0627</th>
<th>NQF Project: Renal Endorsement Maintenance 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>(for Endorsement Maintenance Review)</td>
<td></td>
</tr>
<tr>
<td>Original Endorsement Date: Dec 04, 2009</td>
<td>Most Recent Endorsement Date: Dec 04, 2009</td>
</tr>
</tbody>
</table>

### BRIEF MEASURE INFORMATION

<table>
<thead>
<tr>
<th>De.1 Measure Title:</th>
<th>Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co.1.1 Measure Steward:</td>
<td>ActiveHealth Management</td>
</tr>
<tr>
<td>De.2 Brief Description of Measure:</td>
<td>The percentage of patients with chronic kidney disease and an LDL greater than or equal to 130 mg/dl that have a current refill for a lipid lowering agent.</td>
</tr>
<tr>
<td>2a1.1 Numerator Statement:</td>
<td>Patients with a current refill for a lipid lowering agent.</td>
</tr>
<tr>
<td>2a1.4 Denominator Statement:</td>
<td>All patients, ages 18 and older, diagnosed with chronic kidney disease, including CKD stage 5, dialysis, or kidney transplant, and an LDL level above 130 mg/dL.</td>
</tr>
<tr>
<td>2a1.8 Denominator Exclusions:</td>
<td>Specific Exclusions: None</td>
</tr>
<tr>
<td>General Exclusions:</td>
<td>Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months; Patients who have been in a skilled nursing facility in the last 3 months; Patient or provider feedback indicating allergy or intolerance to the drug in the past; Patient or provider feedback indicating that there is a contraindication to adding the drug</td>
</tr>
</tbody>
</table>

| 1.1 Measure Type: | Process |
| 2a1. 25-26 Data Source: | Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Laboratory, Electronic Clinical Data: Pharmacy, Patient Reported Data/Survey |

1.2-1.4 Is this measure paired with another measure? No

De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed): n/a

### STAFF NOTES (issues or questions regarding any criteria)

**Comments on Conditions for Consideration:**

Is the measure untested? Yes ☐ No ☐ If untested, explain how it meets criteria for consideration for time-limited endorsement:

1. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (check De.5):
5. Similar/related endorsed or submitted measures (check 5.1):
Other Criteria:

Staff Reviewer Name(s):
1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See guidance on evidence. Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact:  

(The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

1a.1 Demonstrated High Impact Aspect of Healthcare:  

Affects large numbers, A leading cause of morbidity/mortality, Patient/societal consequences of poor quality, Severity of illness

1a.2 If “Other,” please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):

The incidence of Atherosclerotic Cardiovascular Disease (ACVD) is significantly higher in patients with Chronic Kidney Disease (CKD) compared to the general population, and is similar to patients with previous Cardiovascular Disease (CVD). Moreover, the survival of patients with CKD is poor, in large part due to AVCD. There is strong evidence that dyslipidemia is one of the leading causes of ACVD.

1a.4 Citations for Evidence of High Impact cited in 1a.3:  


1b. Opportunity for Improvement:  

(There is a demonstrated performance gap - variability or overall less than optimal performance)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:  

Elevated LDL cholesterol levels in patients with CKD are associated with increased mortality and morbidity from CVD. Treatment of patients with elevated LDL cholesterol with lipid lowering therapy reduces the risk of adverse cardiovascular events. Several national guidelines advocate for the use of lipid lowering therapy in patients with CKD and elevated LDL levels.
The benefits of using this measure is increased awareness of the need to screen for and to treat dyslipidemia according to national guidelines. Appropriate compliance with this measure should result in an increase in the treatment of patient with CKD and increased cardiovascular risk, and a reduction in morbidity and mortality for this group of patients.

1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers): [For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]

Despite the presence of evidence for the importance of appropriate management of hyperlipidemia in CKD, and national guidelines recommending the use of lipid lowering therapy in patients with LDL levels greater than 100mg/dl, the proportion of CKD patients with LDL cholesterol levels at goal shows significant room for improvement.

Based on our data collected from a population of 13 million, we found 185 people, for whom we received both diagnoses and lab data, who fulfilled the denominator. Out of these, the compliance for use of a lipid-lowering agent in people with chronic kidney disease and an LDL greater than or equal to 130 was found to be 54%.

This was also demonstrated in a study, which included 166 primary care physicians caring for over 300,000 adult patients, including 11,774 patients with CKD. Overall, less than half of patients with CKD had LDL cholesterol levels less than 100mg/dl.

1b.3 Citations for Data on Performance Gap: [For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included] Based on our data collected across our entire population of 13 million, we found 185 people, for whom we received both diagnoses and lab data, who fulfilled the denominator. Out of these, the compliance for use of a lipid-lowering agent in people with chronic kidney disease and an LDL greater than or equal to 130 was found to be 54%.

In the study mentioned in section 1b.2, the data included a sample of 11,774 patients with Stage 3 and Stage 4 CKD, being followed by one of 166 primary care physicians in one of 15 ambulatory health centers in Massachusetts. There were quality of care measures in four primary domains. The domains included (1) monitoring stage of CKD, (2) cardiovascular risk management, (3) metabolic bone disease and anemia monitoring and (4) drug safety. All measures were assessed in the year following July 1, 2008 to allow a minimum of 1 year following the initial diagnosis of CKD prior to assessing clinical performance.

1b.4 Summary of Data on Disparities by Population Group: [For Maintenance – Descriptive statistics for performance results for this measure by population group]

There was statistically significant variability in the number of patients adequately treated for dyslipidemia in different groups based on ethnicity (black, 32.3% vs. white, 45.6%), gender (male, 51.4% vs. female, 39.7%), type of insurance (commercial, 43.2% vs. uninsured, 25.8%), and presence of co-morbid conditions (e.g. diabetes, hypertension, CVD).

1b.5 Citations for Data on Disparities Cited in 1b.4: [For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included] The data included a sample of 11,774 patients with Stage 3 and Stage 4 CKD, being followed by one of 166 primary care physicians in one of 15 ambulatory health centers in Massachusetts. There were quality of care measures in four primary domains. The domains included (1) monitoring stage of CKD, (2) cardiovascular risk management, (3) metabolic bone disease and anemia monitoring and (4) drug safety. All measures were assessed in the year following July 1, 2008 to allow a minimum of 1 year following the initial diagnosis of CKD prior to assessing clinical performance.


1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.) Is the measure focus a health outcome? Yes ☐ No ☐ If not a health outcome, rate the body of evidence.

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Quality</th>
<th>Consistency</th>
<th>Does the measure pass subcriterion 1c?</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>H</td>
<td>H</td>
<td>Yes</td>
</tr>
</tbody>
</table>

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
**NQF #0627 Chronic Kidney Disease with LDL Greater than or equal to 130 - Use of Lipid Lowering Agent**

<table>
<thead>
<tr>
<th>M-H</th>
<th>M-H</th>
<th>M-H</th>
<th>Yes □</th>
</tr>
</thead>
<tbody>
<tr>
<td>L</td>
<td>M-H</td>
<td>M</td>
<td>Yes □ IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No □</td>
</tr>
<tr>
<td>M-H</td>
<td>L</td>
<td>M-H</td>
<td>Yes □ IF potential benefits to patients clearly outweigh potential harms: otherwise No □</td>
</tr>
<tr>
<td>L-M-H</td>
<td>L-M-H</td>
<td>L</td>
<td>No □</td>
</tr>
</tbody>
</table>

**Health outcome** – rationale supports relationship to at least one healthcare structure, process, intervention, or service

<table>
<thead>
<tr>
<th>Does the measure pass subcriterion 1c?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes □ IF rationale supports relationship</td>
</tr>
</tbody>
</table>

### 1c.1 Structure-Process-Outcome Relationship

Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process-health outcome; intermediate clinical outcome-health outcome;

The focus of this measure is primarily improvement in health outcome. The link is process → health outcome.

### 1c.2-3 Type of Evidence

Check all that apply:

- Clinical Practice Guideline
- Selected individual studies (rather than entire body of evidence)

### 1c.4 Directness of Evidence to the Specified Measure

State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population:

Dyslipidemia in chronic kidney disease is a central topic and relates directly to the measure. The measure evaluates the same population recommended in the literature.

### 1c.5 Quantity of Studies in the Body of Evidence

Total number of studies, not articles: The guidelines reviewed and summarized the results of 32 studies which discuss the prevalence of dyslipidemia in adults, children/adolescents, and patients with kidney disease, and the association with progression of kidney disease.

### 1c.6 Quality of Body of Evidence

Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events:

There is evidence of significantly elevated risk for CVD in patients with CKD. There is also significant evidence of the benefit of treatment of patients with high risk for CVD, with lipid lowering therapy, especially statins, in the presence of elevated LDL cholesterol levels. The ATP III guidelines recommend the treatment of the highest risk patients (10 year risk of CVD >20%) with cholesterol lowering therapy for elevated cholesterol levels > 100mg/dl. Evidence suggests that 10 years risk for CVD in patients with CKD is >20%, so they belong in this highest risk category.

Although there are no randomized trials that evaluate the treatment of elevated LDL cholesterol in patients with CKD, there is convincing indirect evidence of benefit as described above.

There is evidence in the published subsequent to the guidelines that proves an association between LDL cholesterol levels and the risk of CVD. Cardiovascular event rates have a linear correlation with the level of LDL.

### 1c.7 Consistency of Results across Studies

Summarize the consistency of the magnitude and direction of the effect:

The studies included are of mixed quality.

Several observational studies establish the strong association of CKD and hyperlipidemia.

There are no randomized controlled trials testing the hypothesis that dyslipidemias cause ACVD in patients with CKD. However, in an observational study of 3,716 patients initiating treatment for Stage 5 CKD in 1996, the use of statins in 362 (9.7%) was independently associated with lower all-cause mortality and a reduction in CVD deaths during follow-up, suggesting that dyslipidemia plays an important role in the progression of ACVD in patients with advanced CKD (Seliger SL, Weiss NS, Gillen DL, et al: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2002).

### 1c.8 Net Benefit

Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit...
In the absence of strong evidence to the contrary, it is reasonable to assume that statins will reduce LDL and thereby ACVD in most patients with CKD. Statins are clearly the most effective class of antilipemic agents for reducing LDL. There is established benefits to treating patients with elevated LDL.

1c.9 Grading of Strength/Quality of the Body of Evidence. Has the body of evidence been graded? Yes

1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: National Kidney Foundation, K/DOQI

1c.11 System Used for Grading the Body of Evidence: Other

1c.12 If other, identify and describe the grading scale with definitions: The overall strength of each guideline statement was rated by assigning either “A,” “B,” or “C”.

An “A” rating indicates “it is strongly recommended that clinicians routinely follow the guideline for eligible patients. There is strong evidence that the practice improves net health outcomes, and benefits substantially outweigh harms.” There were no guidelines that were assigned an “A” level recommendation.

The “B” rating indicates “it is recommended that clinicians routinely follow the guideline for eligible patients. There is moderate evidence that the practice improves net health outcomes.”

A “C” rating indicates “it is recommended that clinicians consider following the guideline for eligible patients. This recommendation is based on either weak evidence, poor evidence or on the opinions of the Work Group and reviewers, that the practice might improve net health outcomes.”

1c.13 Grade Assigned to the Body of Evidence: moderate evidence

1c.14 Summary of Controversy/Contradictory Evidence: There is no contradictory evidence.

1c.15 Citations for Evidence other than Guidelines(Guidelines addressed below): See above.

1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #): 4.2. For adults with Stage 5 CKD and LDL>100 mg/dL (>2.59 mmol/L), treatment should be considered to reduce LDL to <100 mg/dL (<2.59 mmol/L). (B)


1c.18 National Guideline Clearinghouse or other URL: http://www.kidney.org/professionals/KDOQI/guidelines_lipids/toc.htm

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? Yes

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: National Kidney Foundation, K/DOQI

1c.21 System Used for Grading the Strength of Guideline Recommendation: Other

1c.22 If other, identify and describe the grading scale with definitions: The overall strength of each guideline statement was rated by assigning either “A,” “B,” or “C”.

An “A” rating indicates “it is strongly recommended that clinicians routinely follow the guideline for eligible patients. There is strong evidence that the practice improves net health outcomes, and benefits substantially outweigh harms.” There were no guidelines that
were assigned an “A” level recommendation.

The “B” rating indicates “it is recommended that clinicians routinely follow the guideline for eligible patients. There is moderate evidence that the practice improves net health outcomes.”

A “C” rating indicates “it is recommended that clinicians consider following the guideline for eligible patients. This recommendation is based on either weak evidence, poor evidence or on the opinions of the Work Group and reviewers, that the practice might improve net health outcomes.”

1c.23 Grade Assigned to the Recommendation: **B**

1c.24 Rationale for Using this Guideline Over Others: National Kidney Foundation, K/DOQI, is a nationally recognized body.

Based on the NQF descriptions for rating the evidence, what was the developer’s assessment of the quantity, quality, and consistency of the body of evidence?

<table>
<thead>
<tr>
<th>1c.25 Quantity</th>
<th>1c.26 Quality</th>
<th>1c.27 Consistency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate</td>
<td>Moderate</td>
<td>High</td>
</tr>
</tbody>
</table>

Was the threshold criterion, Importance to Measure and Report, met? (1a & 1b must be rated moderate or high and 1c yes)  
Yes □  No □

Provide rationale based on specific subcriteria:

For a new measure if the Committee votes NO, then STOP.  
For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

---

### 2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. **(evaluation criteria)**

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See guidance on measure testing.

**S.1 Measure Web Page**  
*(In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained).* Do you have a web page where current detailed specifications for this measure can be obtained?  **Yes**

**S.2 If yes, provide web page URL:**  
http://www.activehealth.net/nqf-measures.php

#### 2a. RELIABILITY. Precise Specifications and Reliability Testing:  
**H □ M □ L □ I □**

**2a1. Precise Measure Specifications.** *(The measure specifications precise and unambiguous.)*

**2a1.1 Numerator Statement** *(Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome):*

Patients with a current refill for a lipid lowering agent.

**2a1.2 Numerator Time Window** *(The time period in which the target process, condition, event, or outcome is eligible for inclusion):*

A drug total day-supply that extends within 30 days of the measurement date.

**2a1.3 Numerator Details** *(All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses: NUMERATOR)*

1. The denominator is true
2. One of the following is correct:
NQF #0627 Chronic Kidney Disease with LDL Greater than or equal to 130 - Use of Lipid Lowering Agent

| 2a1.4 Denominator Statement (Brief, narrative description of the target population being measured): |
| All patients, ages 18 and older, diagnosed with chronic kidney disease, including CKD stage 5, dialysis, or kidney transplant, and an LDL level above 130 mg/dL. |

| 2a1.5 Target Population Category (Check all the populations for which the measure is specified and tested if any): |
| Adult/Elderly Care |

| 2a1.6 Denominator Time Window (The time period in which cases are eligible for inclusion): |
| 3 years |

| 2a1.7 Denominator Details (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses): |
| DENOMINATOR |
| All of the following are correct: |
| 1. If patient age >= 18 years |
| 2. Presence of at least 1 LDL VALUE >= 130 in the past 6 months |
| 3. One of the following is correct: |
| a. CKD Stage 5 Validation is confirmed (see below) |
| b. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 3 years |

CKD Stage 5 Validation

One of the following is correct:

| 1. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from EHR data |
| 2. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from EHR data |
| 3. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from disability data |
| 4. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from disability data |
| 5. Presence of at least 2 CKD STAGE 5 diagnosis in the past 12 months at least 3 months apart from claims data |
| 6. Presence of at least 2 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months at least 3 months apart from claims data |
7. All of the following are correct:
   a. Presence of at least 2 CKD - NOS diagnosis in the past 12 months at least 3 months apart from claims data
   b. Presence of at least 1 result for creatinine clearance between 0.1 And 14 in the past
   c. Patient age >= 18 years

8. Presence of at least 2 DIALYSIS CHRONIC (CPT) procedure in the past 12 months

9. Presence of patient data confirming at least 1 PDD - DIALYSIS in the past 12 months

CKD Stage 5 Validation Exclusion

The following is correct:

1. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 12 months

Note: A 3-month time window has been added to certain timeframes to account for the inherent delay in the acquisition of administrative claims data.

Note: A current refill is defined as a refill in which the total day supply of a drug plus a grace period of an additional 30 days extends into the end of the measurement window.

Code Set:

<table>
<thead>
<tr>
<th>NQF ID</th>
<th>Denominator / Numerator</th>
<th>Element Name</th>
<th>Code ID</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581</td>
<td>NEPHROTIC SYNDROME</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.0</td>
<td>NEPHROTIC SYNDROME W/LESION PROLIFERATIVE GLN</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.1</td>
<td>NEPHROTIC SYNDROME W/LESION MEMBRANOUS GLN</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.2</td>
<td>NEPHROTIC SYND W/LESION MEMBRANOPROLIFERAT GLN</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.3</td>
<td>NEPHROTIC SYND W/LES MIN CHG GLOMERULONEPHRIT</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.8</td>
<td>NEPHROTIC SYND W/OTH SPEC PATHAL LESION KIDNEY</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.81</td>
<td>NEPHROTIC SYND W/OTH PATHAL LES DZ CLASS ELSW</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.89</td>
<td>OTH NEPHROTIC SYND W/SPEC PATHAL LESION KIDNEY</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>581.9</td>
<td>NEPHROTIC SYNDROME W/UNSPEC PATHAL LESION KIDNEY</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>585</td>
<td>CHRONIC KIDNEY DISEASE</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>585.9</td>
<td>CHRONIC KIDNEY DISEASE UNSPECIFIED</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD - NOS</td>
<td>587</td>
<td>UNSPECIFIED RENAL SCLEROSIS</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>458.21</td>
<td>HYPOTENSION OF HEMODIALYSIS</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>585.5</td>
<td>CHRONIC KIDNEY DISEASE STAGE V</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>585.6</td>
<td>End stage renal disease</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>996.56</td>
<td>MECH COMPS DUE PERITONEAL DIALYSIS CATHETER</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>996.68</td>
<td>INF&amp;INFAM REACT DUE PERITON DIALYSIS CATHETER</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>996.73</td>
<td>OTH COMPS DUE RENAL DIALYSIS DEVICE IMPLANT&amp;GFT</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>E870.2</td>
<td>ACC CUT PUNCT PERF/HEMORR DUR DIALYSIS/PERFUSION</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>E871.2</td>
<td>FOREIGN OBJ LEFT IN BODY DUR DIALYSIS/PERFUSION</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>E874.2</td>
<td>MECH FAIL-INSTRUMNT/APPARATUS DUR DIALYS-PERFUS</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>E879.1</td>
<td>ABNORMAL REACTION/COMPLICAT D/T KIDNEY DIALYSIS</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>V56</td>
<td>ENCOUNTER DIALYSIS AND DIALYSIS CATHETER CARE</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>V56.0</td>
<td>ENCOUNTER FOR EXTRACORPOREAL DIALYSIS</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>V56.1</td>
<td>FITTING&amp;ADJ EXTRACORPOREAL DIALYSIS CATHETER</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>Denominator *CKD STAGE 5</td>
<td>V56.2</td>
<td>FITTING&amp;ADJUSTMENT PERITONEAL DIALYSIS CATHETER</td>
<td></td>
</tr>
<tr>
<td>Denominator</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>CKD STAGE 5 V56.3 ENCOUNTER FOR ADEQUACY TESTING FOR DIALYSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>CKD STAGE 5 V56.31 ENCOUNTER FOR ADEQUACY TESTING FOR HEMODIALYSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>CKD STAGE 5 V56.32 ENCOUNTER ADEQUACY TESTING PERITONEAL DIALYSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>CKD STAGE 5 V56.8 ENCOUNTER OTHER DIALYSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 0882 MISCELLANEOUS DIALYSIS - Home dialysis aid visit</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90918 ESRD FULL MO &lt;2 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90919 ESRD FULL MO 2-11 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90920 ESRD FULL MO 12-19 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90921 ESRD FULL MO 20+ YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90922 ESRD &lt; FULL MO PR D &lt;2 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90923 ESRD &lt; FULL MO PR D 2-11 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90924 ESRD &lt; FULL MO PR D 12-19 YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) 90925 ESRD &lt; FULL MO PR D 20+ YR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1800 INPATIENT RENAL DIALYSIS - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1801 INPATIENT RENAL DIALYSIS - GENERAL - HEMODIALYSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1802 INPATIENT PERITONEAL DIALYSIS (NON-CAPD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1803 INPATIENT CONTINUOUS DIALYSIS - (CAPD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1804 INPATIENT CONTINUOUS DIALYSIS - (CCPD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1809 INPATIENT DIALYSIS - OTHER</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1820 HEMODIALYSIS - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1821 HEMODIALYSIS - COMPOSITE OR OTHER</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1822 HEMODIALYSIS - HOME SUPPLIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1823 HEMODIALYSIS - HOME SUPPLIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1824 HEMODIALYSIS - MAINTENANCE 100%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1825 HEMODIALYSIS - SUPPORT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1829 HEMODIALYSIS - OTHER OUTPATIENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1830 PERITONEAL DIALYSIS - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1831 PERITONEAL DIALYSIS - COMPOSITE OR OTHER RATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1832 PERITONEAL DIALYSIS - HOME SUPPLIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1833 PERITONEAL DIALYSIS - HOME EQUIPMENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1834 PERITONEAL DIALYSIS - MAINTENANCE 100%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1835 PERITONEAL DIALYSIS - SUPPORT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1839 PERITONEAL DIALYSIS - OTHER OUTPATIENT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1840 CAPD - OUTPATIENT - HOME - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1841 CAPD - COMPOSITE OR OTHER RATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1842 CAPD - HOME SUPPLIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1843 CAPD - HOME EQUIPMENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1844 CAPD - MAINTENANCE 100%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1845 CAPD - SUPPORT SYSTEMS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1849 CAPD - OTHER OUTPATIENT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1850 CCPD - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1851 CCPD - COMPOSITE OR OTHER RATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1852 CCPD - HOME SUPPLIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1853 CCPD - HOME EQUIPMENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1854 CCPD - MAINTENANCE 100%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1855 CCPD - SUPPORT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1859 CCPD - OTHER OUTPATIENT SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1880 MISCELLANEOUS DIALYSIS - GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1881 MISCELLANEOUS DIALYSIS - ULTRAFLTRATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) _1889 MISCELLANEOUS DIALYSIS - OTHER</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>627</td>
<td><strong>DIALYSIS CHRONIC (CPT) G0308 ESRD REL SRVC DUR TX PTS UND 2 YRS; 4/&gt; VSTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### NQF #0627 Chronic Kidney Disease with LDL Greater than or equal to 130 - Use of Lipid Lowering Agent

<table>
<thead>
<tr>
<th>Denominator</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0309</td>
<td>ESRD REL SRVC DUR TX UND 2 YRS; 2/3 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0310</td>
<td>ESRD REL SRVC DUR TX UND 2 YRS AGE; 1 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0311</td>
<td>ESRD REL SRVC DUR TX BETWN 2&amp;11 YR; 4/&gt; VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0312</td>
<td>ESRD REL SRVC DUR TX BETWN 2&amp;11 YR; 2/3 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0313</td>
<td>ESRD REL SRVC DUR TX BETWN 2&amp;11 YR; 1 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0314</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19; 4/&gt; VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0315</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19; 2/3 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0316</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19 YR; 1 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0317</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19 YR; 2/3 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0318</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19 YR; 1 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0319</td>
<td>ESRD REL SRVC DUR TX BETWN 12&amp;19 YR; 2/3 VSTS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0320</td>
<td>ESRD REL SRVC HOM DIALYSIS FULL MO; UND 2 YR</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0321</td>
<td>ESRD REL SRVC HOM DIALYSIS FULL MO; 2-11 YRS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0322</td>
<td>ESRD REL SRVC HOM DIALYSIS FULL MO; 12-19 YR</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0323</td>
<td>ESRD REL SRVC HOM DIALYSIS FULL MO; 20 YRS&amp;OLDER</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0324</td>
<td>ESRD REL SERVICE HOME DIALYSIS PER DAY; PT &lt;2 YR</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0325</td>
<td>ESRD REL SERV HOME DIALYSIS PER DAY; PT 2-11 YRS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0326</td>
<td>ESRD REL SERV HOME DIALYSIS PER DAY; PT 12-19 YRS</td>
</tr>
<tr>
<td>DIALYSIS CHRONIC (CPT)</td>
<td>G0327</td>
<td>ESRD REL SERV HOME DIALYSIS PER DAY; PT 20 YRS&amp;OLDER</td>
</tr>
</tbody>
</table>

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.0 ENCOUNTER FOR EXTRACORPOREAL DIALYSIS
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.1 FITTING&ADJ EXTRACORPOREAL DIALYSIS CATHETER
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.2 FITTING&ADJUSTMENT PERITONEAL DIALYSIS CATHETER
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.3 ENCOUNTER FOR ADEQUACY TESTING FOR DIALYSIS
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.31 ENCOUNTER FOR ADEQUACY TESTING FOR HEMODIALYSIS
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.32 ENCOUNTER ADEQUACY TESTING PERITONEAL DIALYSIS
627 Denominator *ESRD/DIALYSIS (ICD-9) V56.8 ENCOUNTER OTHER DIALYSIS
627 Denominator *LDL VALUE 12773-8 Cholesterol in LDL
627 Denominator *LDL VALUE 13457-7 CHOLESTEROL IN LDL
627 Denominator *LDL VALUE 18261-8 Cholesterol in LDL
627 Denominator *LDL VALUE 18262-6 Cholesterol in LDL
627 Denominator *LDL VALUE 2089-1 CHOLESTEROL IN LDL
627 Denominator *LDL VALUE 2090-9 Cholesterol in LDL
627 Denominator *LDL VALUE 9346-8 Lipoprotein beta
627 Denominator *PDD- DIALYSIS AA11214.44689 What health conditions has your doctor said you have? = Kidney Failure (Dialysis)
627 Denominator *PDD- DIALYSIS AA1600.4755 Are you on kidney dialysis? = Yes
627 Denominator *PDD- DIALYSIS AA20620.77113 What health conditions does the member have? = Kidney Failure (Dialysis)
627 Denominator *PDD- DIALYSIS AA3350.10749 Are you receiving hemodialysis? = Yes
627 Denominator *PDD- DIALYSIS AA3355.10764 Are you receiving peritoneal dialysis? = Yes
627 Denominator *PDD- DIALYSIS ATV11214.44689 What health conditions has your doctor said you have? = Kidney Failure (Dialysis)
627 Denominator *PDD- DIALYSIS ATV1600.4755 Are you on kidney dialysis? = Yes
627 Denominator *PDD- DIALYSIS ATV20620.77113 What health conditions does the member have? = Kidney Failure (Dialysis)
627 Denominator *PDD- DIALYSIS ATV20936.78257 What health conditions does the member have? = Kidney Failure (Dialysis)
627 Denominator *PDD- DIALYSIS ATV3350.10749 Are you receiving hemodialysis? = Yes
627 Denominator *PDD- DIALYSIS ATV3355.10764 Are you receiving peritoneal dialysis? = Yes
627 Denominator *PDD- DIALYSIS HMT94.1 Are you on kidney dialysis? Dialysis is used to clean wastes from the blood after the kidneys have failed. = Yes
627 Denominator *PDD- DIALYSIS PHR94.1 On kidney dialysis? = Yes
627 Denominator *PDD- DIALYSIS PHR100260001.1 Do you know the stage of your kidney disease? = I get dialysis regularly
627 Denominator *PDD- DIALYSIS PHR102770001.1 Which type of dialysis are you getting? = Hemodialysis
627 Denominator *PDD- DIALYSIS PHR102770001.2 Which type of dialysis are you getting? = Peritoneal dialysis
627 Denominator *PDD- DIALYSIS PHY617.1 Are you receiving hemodialysis? = Yes
627 Denominator *TRANSPLANT RENAL (CPT) 55.6 TRANSPLANT OF KIDNEY
627 Denominator *TRANSPLANT RENAL (CPT) 55.61 RENAL AUTOTRANSPLANTATION
627 Denominator *TRANSPLANT RENAL (CPT) 55.69 OTHER KIDNEY TRANSPLANTATION
627 Denominator *TRANSPLANT RENAL (CPT) 50360 RNL ALTRANSPJ IMPLTJ GRF W/O RCP NFRC
627 Denominator *TRANSPLANT RENAL (CPT) 50365 RNL ALTRANSPJ IMPLTJ GRF W/RCP NFRC
627 Denominator *TRANSPLANT RENAL (CPT) 50380 RNL AUTOTRANSPLJ RIMPLTJ KDN
627 Denominator *TRANSPLANT RENAL (CPT) 1367 OPERATING ROOM SERVICES - KIDNEY TRANSPLANTATION
627 Denominator *TRANSPLANT RENAL (CPT) S2065 SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION

2a1.8 Denominator Exclusions (Brief narrative description of exclusions from the target population):
Specific Exclusions:

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
None

General Exclusions:
• Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
• Patients who have been in a skilled nursing facility in the last 3 months
• Patient or provider feedback indicating allergy or intolerance to the drug in the past
• Patient or provider feedback indicating that there is a contraindication to adding the drug

2a1.9 Denominator Exclusion Details (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):
General Exclusions:
• Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
• Patients who have been in a skilled nursing facility in the last 3 months
• Patient or provider feedback indicating allergy or intolerance to the drug in the past
• Patient or provider feedback indicating that there is a contraindication to adding the drug

Note: A 3-month window has been added to certain timeframes to account for the inherent delay in the acquisition of administrative claims data.

Note: A current refill is defined as a refill in which the total days supply of a drug extends to the end of the measurement window plus a grace period of an additional 30 days.

2a1.10 Stratification Details/Variables (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):
The results are not stratified.

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): No risk adjustment or risk stratification 2a1.12 If "Other," please describe:

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):
No risk model applied to this measure.

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: Rate/proportion

2a1.19 Interpretation of Score (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): Better quality = Higher score

2a1.20 Calculation Algorithm/Measure Logic (Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):
PERFORMANCE MEASURE RULE:
Chronic Kidney Disease with LDL = 130 – Consider Adding a Lipid Lowering Agent

DENOMINATOR
All of the following are correct:

1. If patient age ≥ 18 years
2. Presence of at least 1 LDL VALUE ≥ 130 in the past 6 months
3. One of the following is correct:
   a. CKD Stage 5 Validation is confirmed (see below)
   b. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 3 years

DENOMINATOR EXCLUSIONS

None

NUMERATOR

1. The denominator is true
2. One of the following is correct:
   a. Presence of at least 1 current refill for LIPID LOWERING AGENTS
   b. Presence of patient data confirming at least 1 LIPID LOWERING AGENTS in the past 6 months

VALIDATION RULES

CKD Stage 5 Validation

One of the following is correct:

1. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from EHR data
2. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from EHR data
3. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from disability data
4. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from disability data
5. Presence of at least 2 CKD STAGE 5 diagnosis in the past 12 months at least 3 months apart from claims data
6. Presence of at least 2 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months at least 3 months apart from claims data
7. All of the following are correct:
   a. Presence of at least 2 CKD - NOS diagnosis in the past 12 months at least 3 months apart from claims data
   b. Presence of at least 1 result for creatinine clearance between 0.1 And 14 in the past
c. Patient age \(\geq 18\) years

8. Presence of at least 2 DIALYSIS CHRONIC (CPT) procedure in the past 12 months

9. Presence of patient data confirming at least 1 PDD - DIALYSIS in the past 12 months

CKD Stage 5 Validation Exclusion

The following is correct:

1. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 12 months

Note: A 3-month time window has been added to certain timeframes to account for the inherent delay in the acquisition of administrative claims data.

Note: A current refill is defined as a refill in which the total day supply of a drug plus a grace period of an additional 30 days extends into the end of the measurement window.

2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:
Attachment
Chronic Kidney Disease with LDL Greater than 130 - Algorithm.pdf

2a1.24 Sampling (Survey) Methodology. If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):

Measure is not based on a sample.

2a1.25 Data Source (Check all the sources for which the measure is specified and tested). If other, please describe:

Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory, Electronic Clinical Data : Pharmacy, Patient Reported Data/Survey

2a1.26 Data Source/Data Collection Instrument (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): Data are collected from a number of electronic sources, e.g., health plans, pharmacy-based management systems, electronic health records, patient health records, etc.

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment:

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:
Attachment
627 Chronic Kidney Disease with LDL Greater than 130 - all.xlsx

2a1.33 Level of Analysis (Check the levels of analysis for which the measure is specified and tested):


2a1.34-35 Care Setting (Check all the settings for which the measure is specified and tested):

Ambulatory Care : Clinician Office, Dialysis Facility, Home Health, Hospital/Acute Care Facility

2a2. Reliability Testing. (Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)
2a2.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

All the data for the measures are obtained from electronic sources. Based on the client, we take in electronic data from health plans, pharmacy-based management systems, laboratory systems, personal health records, health risk assessments, and electronic health records. In addition, we can take in data from care management systems. All data feeds are electronic and do not require manual medical chart abstraction.

We have over 21 million patient records across our book of business. The average age of the population is 35 and 51.9% of the population is female. Currently we use a database of approximately over 2 million patient records pulled from multiple populations for testing purposes.

Our testing procedure includes testing the rules on the database of approximately 2 million patient records. We typically review the results for reliability, i.e., did we find the same people on multiple runs and validity, i.e., did we find the appropriate people in the denominator and numerator.

2a2.2 Analytic Method (Describe method of reliability testing & rationale):

All of our quality measures are electronic and all the data used to support the measures are electronic. In addition, we receive the data by electronic feeds. We have internal processes to ensure that we receive valid codes and where appropriate the associated values. Our analytic process includes testing a new rule or algorithm on our test database of 2 million patient records, so that we can be sure of the reliability of the code. At the end of the test, we randomly select patients who are either in the numerator, or in the denominator but not the numerator, to ensure that they met the requirements of the rule. As a part of our reliability testing, we check to ensure we have found the correct people in the denominator or the numerator, across multiple rules with similar definitions. To ensure accuracy, we check a subset of the people who were not in the numerator to ensure that we were accurate in not counting them in the numerator. If we find errors at any stage of the reliability testing, e.g., similar denominators that had significant differences in counts, different compliance rates for similar populations; we update the rules and retest.

2a2.3 Testing Results (Reliability statistics, assessment of adequacy in the context of norms for the test conducted):

The measure algorithms and code sets are all electronic. Once we complete testing the rules and correcting any errors, the rules are deployed in a production environment for our clients. At that point, the rules are considered reliable, i.e., if the rules are run on the same data set we expect to find the same people on a consistent basis.

2b. VALIDITY. Validity, Testing, including all Threats to Validity:  H M L I

2b1.1 Describe how the measure specifications (measure focus, target population, and exclusions) are consistent with the evidence cited in support of the measure focus (criterion 1c) and identify any differences from the evidence:

The K/DOQI clinical guidelines recommend treating adults with Stage 5 CKD with elevated LDL. The guidelines recommend that for patients with LDL = 130 mg/dL initiate therapeutic lifestyle changes and low dose statin. For patients who are not able to tolerate a statin they advocate adding a second line agent such as a bile acid sequestrant or nicotinic acid. Based on the guideline’s recommendations, our algorithm finds all adult patients with electronic evidence of Stage 5 CKD, who have had an LDL = 130, consistent with the existing guidelines.

2b2. Validation Testing. (Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.)

2b2.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

The data for the measure are obtained from electronic sources. Based on the client, we take in electronic data from health plans, pharmacy-based management systems, laboratory systems, personal health records, health risk assessments, and electronic health records. In addition, we can take in data from care management systems. All data feeds are electronic and do not require manual medical chart abstraction.

2b2.2 Analytic Method (Describe method of validity testing and rationale; if face validity, describe systematic assessment):

All of our quality measures are electronic and all the data used to support the measures are electronic. In addition, we receive the data by electronic feeds. We have internal processes to ensure that we receive valid codes and where appropriate the associated values. Currently we use a database of approximately 2 million patient records for testing purposes. Our analytic process includes testing a new rule or algorithm on the standard data set so that we can be sure of the reliability of the code. At the end of the test, we randomly select patients who are either in the numerator, or in the denominator but not the numerator, to ensure that they met...
the requirements of the rule. As a part of our validity testing, we check to ensure we have found the correct people in the
denominator or the numerator. To ensure accuracy, we check a subset of the people who were not in the numerator to ensure that
we were accurate in not counting them in the numerator. If we find errors at any stage of the reliability testing, e.g., similar
denominators that had differences in counts, compliance rates for similar populations that differ, then we update the rules and
retest.
Further, to ensure that we obtain valid results once the measures are deployed, when we run the measure for a client we evaluate
the results to ensure they are consistent with what we have found in the past for the client and across our book of business.

2b2.3 Testing Results *(Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment):*

The algorithms and code sets used for the measures are all electronic. Once we test the rules, and correct any errors, the rules are
deployed in a production environment for our clients. At that point, the rule is considered reliable, that is we are finding the
appropriate people in the denominator and numerator.

**POTENTIAL THREATS TO VALIDITY.** *(All potential threats to validity were appropriately tested with adequate results.)*

2b3. Measure Exclusions. *(Exclusions were supported by the clinical evidence in 1c or appropriately tested with results
demonstrating the need to specify them.)*

2b3.1 Data/Sample for analysis of exclusions *(Description of the data or sample including number of measured entities; number
of patients; dates of data; if a sample, characteristics of the entities included):*

There are no specific exclusions to this measure. For all of our rules, we apply general exclusions. In particular, we exclude people
with a diagnosis of metastatic cancer or cancer treatment in the 6 month prior to the measurement date. In addition, we exclude
patients who were in a skilled nursing facility 3 months before the measurement date.

2b3.2 Analytic Method *(Describe type of analysis and rationale for examining exclusions, including exclusion related to patient
preference):*

There are no exclusions.

2b3.3 Results *(Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):*

There are no exclusions.

2b4. Risk Adjustment Strategy. *(For outcome measures, adjustment for differences in case mix (severity) across measured
entities was appropriately tested with adequate results.)*

2b4.1 Data/Sample *(Description of the data or sample including number of measured entities; number of patients; dates of data; if
a sample, characteristics of the entities included):*

We do not apply risk adjustment to our rules.

2b4.2 Analytic Method *(Describe methods and rationale for development and testing of risk model or risk stratification including
selection of factors/variables):*

We do not apply risk adjustment to our rules.

2b4.3 Testing Results *(Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk
model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot,
and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of
relationship of risk factors to the outcome and differences in outcomes among the strata):*

We do not apply risk adjustment to our rules.

2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of
adjustment: To satisfy the ability to apply evidence-based risk stratification protocols, we would have to collect electronic data to
support the stratification, systematically; and often these data are not readily captured using standard electronic feeds. Other
potential risk factors, e.g. race, gender, age, and socioeconomic status, relate to disparities in care, and except for age would be
difficult to capture. In addition, risk stratification for a process measure might not be applicable
We anticipate that once electronic health records and clinical data become more prevalent and robust, we will be able to capture
these additional data for routine risk adjustment.
2b5. Identification of Meaningful Differences in Performance. (The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

2b5.1 Data/Sample (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):
Our ability to analyze measures across different populations is limited by the characteristics of a specific client population. Since the rules are electronic, they are applied consistently, independent of the population characteristics. For example running this measure on a young population, may result in a lower denominator and compliance rate, compared to evaluating the measure across an older population.

2b5.2 Analytic Method (Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):
See comments above.

2b5.3 Results (Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):
See comments above.

2b6. Comparability of Multiple Data Sources/Methods. (If specified for more than one data source, the various approaches result in comparable scores.)

2b6.1 Data/Sample (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):
We receive electronic data from multiple sources – health plan, electronic health record, personal health record, etc. Independent of the sources, all the available data about a patient are aggregated into a single patient record for use in performance measurement. Therefore, for an individual patient the record will include claims data, clinical data from an electronic health record, or a self-reported data from a patient health record. Based on this, we do not typically conduct analyses based on disparate sources of data. Instead, the rules contain redundancies to accommodate the different sources of data or the absence of specific data based on the source.

2b6.2 Analytic Method (Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):
See comments above.

2b6.3 Testing Results (Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted):
See comments above.

2c. Disparities in Care: H M L I NA (If applicable, the measure specifications allow identification of disparities.)
2c.1 If measure is stratified for disparities, provide stratified results (Scores by stratified categories/cohorts): We do not stratify our measures for disparities.

2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:
To stratify based on disparities, would require that we receive electronic data in our standard feeds that we do not currently receive, e.g., race, ethnicity, socioeconomic status. We anticipate that once electronic health records and clinical data become more prevalent and robust, we will be able to capture these additional data for routine use including stratification disparities.

2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, Scientific Acceptability of Measure Properties, met? (Reliability and Validity must be rated moderate or high) Yes No
Provide rationale based on specific subcriteria:
### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

**C.1 Intended Purpose/ Use** (Check all the purposes and/or uses for which the measure is intended): Payment Program, Public Reporting, Quality Improvement (Internal to the specific organization)

**3.1 Current Use** (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting, Quality Improvement (Internal to the specific organization)

#### 3a. Usefulness for Public Reporting: H☐ M☐ L☐ I☐
(The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

Traditionally, we have reported our measures to clients who then publish the results publicly. We are in the process of working with clients who are a part of a number of initiative including patient-centered medical homes and accountable care organizations. We anticipate that with these new initiatives, that we will deploy our quality measures, the results of which should be part of the public reporting and quality initiative programs.

3a.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: The measures performance results are useful because there is independent evidence that patients with CKD do not necessarily receive the appropriate intervention especially in the primary care setting.

Patients with chronic kidney disease are at high risk for cardiovascular events. The detection of dyslipidemia allows for early treatment with statins, which may decrease this risk and reduce subsequent complications and costs.

Providing public reporting of this measure will lead to increased awareness of the need to screen for cardiovascular risk factors in renal patients and where appropriate to treat.

#### 3b. Usefulness for Quality Improvement: H☐ M☐ L☐ I☐
(The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s): [For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].

Traditionally, we have reported our measures to clients who then publish the results publicly. We are in the process of working with clients who are a part of a number of initiative including patient-centered medical homes and accountable care organizations. We anticipate that with these new initiatives, that we will deploy our quality measures, the results of which should be part of the public reporting and quality initiative programs.

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results: The measures performance results are useful because there is independent evidence that patients with CKD do not necessarily receive the appropriate intervention especially in the primary care setting.

Patients with chronic kidney disease are at high risk for cardiovascular events. The detection of dyslipidemia allows for early...
treatment with statins, which may decrease this risk and reduce subsequent complications and costs.

Providing public reporting of this measure will lead to increased awareness of the need to screen for cardiovascular risk factors in renal patients and where appropriate to treat.

Overall, to what extent was the criterion, Usability, met?  H □ M □ L □ I □
Provide rationale based on specific subcriteria:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H □ M □ L □ I □

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).

Data used in the measure are:
generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition,
Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims), Other
personal health record, disease management system

4b. Electronic Sources: H □ M □ L □ I □

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): ALL data elements are in a combination of electronic sources

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H □ M □ L □ I □

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:
We use a combination of data sources to mitigate the risk of inaccuracies or errors. We recognize that generally, electronic data have inherent errors and inaccuracies related to incorrect coding, or missing data, which can result in less specificity in the definition of the denominator and/or the numerator. To minimize these errors and inaccuracies, we use clinically enriched data (laboratory results, medication lists) to augment the data. In addition, where possible, we corroborate the data, for example if we receive an ICD-9 code for diabetes from claims, we also build include in the rule the requirement for diabetic medications. We have a mechanism in place to solicit feedback from providers via a feedback form, if they detect errors with the measure.

We do not anticipate significant unintended consequences from the implementation of the measure. Our measures are all developed from evidence-based literature or from clinical practice guidelines and are designed to encourage appropriate care of the patient.

4d. Data Collection Strategy/Implementation: H □ M □ L □ I □

A.2 Please check if either of the following apply (regarding proprietary measures): Proprietary measure

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):
Generally, we have learned that we have to be flexible to take in data from all possible sources. We have also heard from providers, that they prefer that the rules err on the side of specificity, e.g., lessen the risk of false positives, that is, identifying the wrong patient for the denominator and that they want a mechanism to provide feedback.

Overall, to what extent was the criterion, Feasibility, met? H □ M □ L □ I □
Provide rationale based on specific subcriteria:

OVERALL SUITABILITY FOR ENDORSEMENT
Does the measure meet all the NQF criteria for endorsement? *Yes* ☑ *No* ☐

Rationale:

If the Committee votes No, STOP.

If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (either same measure focus or target population) or competing measures (both the same measure focus and same target population), list the NQF # and title of all related and/or competing measures:

5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s): Are the measure specifications completely harmonized?

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. *(Provide analyses when possible)*:

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner): ActiveHealth Management, 1333 Broadway, New York, New York, 10018

Co.2 Point of Contact: Madhavi, Vemireddy, MD, mvemireddy@activehealth.net, 212-651-8200-

Co.3 Measure Developer if different from Measure Steward: ActiveHealth Management, 1333 Broadway, New York, New York, 10018

Co.4 Point of Contact: Madhavi, Vemireddy, MD, mvemireddy@activehealth.net, 212-651-8200-

Co.5 Submitter: Mureen, Allen, MD, MS, MA, FACP, mallen@activehealth.net, 212-651-8200-, ActiveHealth Management

Co.6 Additional organizations that sponsored/participated in measure development:

Co.7 Public Contact: Mureen, Allen, MD, MS, MA, FACP, mallen (at) activehealth.net, 212-651-8200-, ActiveHealth Management

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations. Describe the members’ role in measure development.

n/a

Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for
<table>
<thead>
<tr>
<th>Measure Developer/Steward Updates and Ongoing Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ad.3 Year the measure was first released:</strong> 2009</td>
</tr>
<tr>
<td><strong>Ad.4 Month and Year of most recent revision:</strong> 06, 2011</td>
</tr>
<tr>
<td><strong>Ad.5 What is your frequency for review/update of this measure?</strong> every 2 years</td>
</tr>
<tr>
<td><strong>Ad.6 When is the next scheduled review/update for this measure?</strong> 10, 2013</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ad.7 Copyright statement:</th>
</tr>
</thead>
<tbody>
<tr>
<td>This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ad.8 Disclaimers:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Ad.9 Additional Information/Comments:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fields 1a.4, 1b.2, and 1b.3 revised on 11/10/2011. A typo was found in section 2a1.34 and corrected on 11/10/2011.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of Submission (MM/DD/YY):</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/30/2011</td>
</tr>
<tr>
<td>NQF ID</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>00074612390</td>
</tr>
<tr>
<td>00074641590</td>
</tr>
<tr>
<td>00074644790</td>
</tr>
<tr>
<td>00074918990</td>
</tr>
<tr>
<td>00074964290</td>
</tr>
<tr>
<td>00075283501</td>
</tr>
<tr>
<td>00075283505</td>
</tr>
<tr>
<td>00075284001</td>
</tr>
<tr>
<td>00075284005</td>
</tr>
<tr>
<td>00075284101</td>
</tr>
<tr>
<td>00075284105</td>
</tr>
<tr>
<td>00075285001</td>
</tr>
<tr>
<td>00075285005</td>
</tr>
<tr>
<td>00078017605</td>
</tr>
<tr>
<td>00078017615</td>
</tr>
<tr>
<td>00078023405</td>
</tr>
<tr>
<td>00078023415</td>
</tr>
<tr>
<td>00078035405</td>
</tr>
<tr>
<td>00078035415</td>
</tr>
<tr>
<td>00084001201</td>
</tr>
<tr>
<td>00084001301</td>
</tr>
<tr>
<td>00084114301</td>
</tr>
<tr>
<td>00084114401</td>
</tr>
<tr>
<td>00087058001</td>
</tr>
<tr>
<td>00087058005</td>
</tr>
<tr>
<td>00087058011</td>
</tr>
<tr>
<td>00087058017</td>
</tr>
<tr>
<td>00087058018</td>
</tr>
<tr>
<td>00087058901</td>
</tr>
<tr>
<td>00087058903</td>
</tr>
<tr>
<td>00087500341</td>
</tr>
<tr>
<td>00087944211</td>
</tr>
<tr>
<td>00088157547</td>
</tr>
<tr>
<td>00093023901</td>
</tr>
<tr>
<td>00093057606</td>
</tr>
<tr>
<td>00093057610</td>
</tr>
<tr>
<td>00093057619</td>
</tr>
<tr>
<td>00093057693</td>
</tr>
<tr>
<td>00093067005</td>
</tr>
<tr>
<td>00093067006</td>
</tr>
<tr>
<td>00093067019</td>
</tr>
<tr>
<td>00093067093</td>
</tr>
<tr>
<td>00093077110</td>
</tr>
<tr>
<td>00093077198</td>
</tr>
<tr>
<td>00093092606</td>
</tr>
<tr>
<td>00093092610</td>
</tr>
<tr>
<td>00093092619</td>
</tr>
<tr>
<td>00093092693</td>
</tr>
<tr>
<td>00093092806</td>
</tr>
<tr>
<td>00093092810</td>
</tr>
<tr>
<td>00093092819</td>
</tr>
<tr>
<td>00093092893</td>
</tr>
<tr>
<td>00093715219</td>
</tr>
<tr>
<td>00093715256</td>
</tr>
<tr>
<td>00093715293</td>
</tr>
<tr>
<td>00093715298</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>00185074301</td>
</tr>
<tr>
<td>00185074401</td>
</tr>
<tr>
<td>00185093997</td>
</tr>
<tr>
<td>00185094097</td>
</tr>
<tr>
<td>00187006050</td>
</tr>
<tr>
<td>00187055510</td>
</tr>
<tr>
<td>00187055710</td>
</tr>
<tr>
<td>00188703010</td>
</tr>
<tr>
<td>00188814410</td>
</tr>
<tr>
<td>00188814510</td>
</tr>
<tr>
<td>00191000401</td>
</tr>
<tr>
<td>00191016510</td>
</tr>
<tr>
<td>00191200201</td>
</tr>
<tr>
<td>00191202010</td>
</tr>
<tr>
<td>00191205001</td>
</tr>
<tr>
<td>00191205010</td>
</tr>
<tr>
<td>00223135101</td>
</tr>
<tr>
<td>00223135201</td>
</tr>
<tr>
<td>00223135301</td>
</tr>
<tr>
<td>00228186710</td>
</tr>
<tr>
<td>00228186796</td>
</tr>
<tr>
<td>00228229510</td>
</tr>
<tr>
<td>00228255206</td>
</tr>
<tr>
<td>00228255250</td>
</tr>
<tr>
<td>00228263306</td>
</tr>
<tr>
<td>00228263406</td>
</tr>
<tr>
<td>00228263506</td>
</tr>
<tr>
<td>00228284010</td>
</tr>
<tr>
<td>00245003623</td>
</tr>
<tr>
<td>00245003660</td>
</tr>
<tr>
<td>00245006011</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>00304049400</td>
</tr>
<tr>
<td>00304075000</td>
</tr>
<tr>
<td>00304169701</td>
</tr>
<tr>
<td>00310075239</td>
</tr>
<tr>
<td>00339565112</td>
</tr>
<tr>
<td>00349602210</td>
</tr>
<tr>
<td>00349602301</td>
</tr>
<tr>
<td>00349847310</td>
</tr>
<tr>
<td>00349848001</td>
</tr>
<tr>
<td>00349848010</td>
</tr>
<tr>
<td>00349864701</td>
</tr>
<tr>
<td>00349884601</td>
</tr>
<tr>
<td>00349884701</td>
</tr>
<tr>
<td>00353208501</td>
</tr>
<tr>
<td>00353208601</td>
</tr>
<tr>
<td>00353244001</td>
</tr>
<tr>
<td>00353297301</td>
</tr>
<tr>
<td>00359075810</td>
</tr>
<tr>
<td>00359075910</td>
</tr>
<tr>
<td>00359076010</td>
</tr>
<tr>
<td>00359076110</td>
</tr>
<tr>
<td>00359076210</td>
</tr>
<tr>
<td>00361214910</td>
</tr>
<tr>
<td>00363345010</td>
</tr>
<tr>
<td>00363503410</td>
</tr>
<tr>
<td>00364106501</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>00536703708</td>
</tr>
<tr>
<td>00536703801</td>
</tr>
<tr>
<td>00537404710</td>
</tr>
<tr>
<td>00537404801</td>
</tr>
<tr>
<td>00537404810</td>
</tr>
<tr>
<td>00537404901</td>
</tr>
<tr>
<td>00537404910</td>
</tr>
<tr>
<td>00537405405</td>
</tr>
<tr>
<td>00537606401</td>
</tr>
<tr>
<td>00537606410</td>
</tr>
<tr>
<td>00537606501</td>
</tr>
<tr>
<td>00537606510</td>
</tr>
<tr>
<td>00556012001</td>
</tr>
<tr>
<td>00556012010</td>
</tr>
<tr>
<td>00556012101</td>
</tr>
<tr>
<td>00556012110</td>
</tr>
<tr>
<td>00556012120</td>
</tr>
<tr>
<td>00556012130</td>
</tr>
<tr>
<td>00580022201</td>
</tr>
<tr>
<td>00580022210</td>
</tr>
<tr>
<td>00580022220</td>
</tr>
<tr>
<td>00580147101</td>
</tr>
<tr>
<td>00580172101</td>
</tr>
<tr>
<td>00580172201</td>
</tr>
<tr>
<td>00580172301</td>
</tr>
<tr>
<td>00580172401</td>
</tr>
<tr>
<td>00591001301</td>
</tr>
<tr>
<td>00591001310</td>
</tr>
<tr>
<td>00591001319</td>
</tr>
<tr>
<td>00591001401</td>
</tr>
<tr>
<td>00591001419</td>
</tr>
<tr>
<td>00591001601</td>
</tr>
<tr>
<td>00591001610</td>
</tr>
<tr>
<td>00591001619</td>
</tr>
<tr>
<td>00591001905</td>
</tr>
<tr>
<td>00591001919</td>
</tr>
<tr>
<td>00591004505</td>
</tr>
<tr>
<td>00591045460</td>
</tr>
<tr>
<td>00591506601</td>
</tr>
<tr>
<td>00591506604</td>
</tr>
<tr>
<td>00591510201</td>
</tr>
<tr>
<td>00591510204</td>
</tr>
<tr>
<td>00598101601</td>
</tr>
<tr>
<td>00598101652</td>
</tr>
<tr>
<td>00598101701</td>
</tr>
<tr>
<td>00598121113</td>
</tr>
<tr>
<td>00598921113</td>
</tr>
<tr>
<td>00603293221</td>
</tr>
<tr>
<td>00603375020</td>
</tr>
<tr>
<td>00603375028</td>
</tr>
<tr>
<td>00603473521</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00814726006</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00814726014</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00814726022</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143106</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143116</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143120</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143206</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143216</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839143220</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523706</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523716</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523806</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523816</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523820</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523906</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523916</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839523920</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839610306</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839610316</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839610320</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839645806</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839645816</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839645820</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839722806</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839722810</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839754606</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839754706</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839754716</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839754806</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839754906</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839778705</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00839778712</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879008201</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879008210</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879502401</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879502410</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879502501</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00879502510</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00892000101</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00892000105</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904062860</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904062880</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904062960</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904062970</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904062980</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904063060</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904063160</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904063170</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904063180</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904063360</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904227060</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904227080</td>
</tr>
<tr>
<td>Numerator *LIPID LOWERING AGENTS 00904227090</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>58016038560</td>
</tr>
<tr>
<td>58016042530</td>
</tr>
<tr>
<td>58016042560</td>
</tr>
<tr>
<td>58016042590</td>
</tr>
<tr>
<td>58016054000</td>
</tr>
<tr>
<td>58016054060</td>
</tr>
<tr>
<td>58016057200</td>
</tr>
<tr>
<td>58016057290</td>
</tr>
<tr>
<td>58016058300</td>
</tr>
<tr>
<td>58016058360</td>
</tr>
<tr>
<td>58016058390</td>
</tr>
<tr>
<td>58016065300</td>
</tr>
<tr>
<td>58016065400</td>
</tr>
<tr>
<td>58016065600</td>
</tr>
<tr>
<td>58016068900</td>
</tr>
<tr>
<td>58016068930</td>
</tr>
<tr>
<td>58016068960</td>
</tr>
<tr>
<td>58016068990</td>
</tr>
<tr>
<td>58016069000</td>
</tr>
<tr>
<td>58016069002</td>
</tr>
<tr>
<td>58016069003</td>
</tr>
<tr>
<td>58016069006</td>
</tr>
<tr>
<td>58016069009</td>
</tr>
<tr>
<td>58016069200</td>
</tr>
<tr>
<td>58016069202</td>
</tr>
<tr>
<td>58016069220</td>
</tr>
<tr>
<td>58016069226</td>
</tr>
<tr>
<td>58016069229</td>
</tr>
<tr>
<td>58016069790</td>
</tr>
<tr>
<td>58016069792</td>
</tr>
<tr>
<td>58016069793</td>
</tr>
<tr>
<td>58016069796</td>
</tr>
<tr>
<td>58016069799</td>
</tr>
<tr>
<td>58016906601</td>
</tr>
<tr>
<td>58016911101</td>
</tr>
<tr>
<td>58016996701</td>
</tr>
<tr>
<td>58469346630</td>
</tr>
<tr>
<td>58469407030</td>
</tr>
<tr>
<td>58469407330</td>
</tr>
<tr>
<td>58469407430</td>
</tr>
<tr>
<td>58469407630</td>
</tr>
<tr>
<td>58864060830</td>
</tr>
<tr>
<td>58864062315</td>
</tr>
<tr>
<td>58864062330</td>
</tr>
<tr>
<td>58864065330</td>
</tr>
<tr>
<td>58864068230</td>
</tr>
<tr>
<td>58864068530</td>
</tr>
<tr>
<td>58864071060</td>
</tr>
<tr>
<td>58864073930</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>627</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>63629340802</td>
</tr>
<tr>
<td>63629340803</td>
</tr>
<tr>
<td>63629340804</td>
</tr>
<tr>
<td>63629356301</td>
</tr>
<tr>
<td>63629358301</td>
</tr>
<tr>
<td>63629358302</td>
</tr>
<tr>
<td>63739011401</td>
</tr>
<tr>
<td>63739011403</td>
</tr>
<tr>
<td>63739028010</td>
</tr>
<tr>
<td>63739028015</td>
</tr>
<tr>
<td>637390280103</td>
</tr>
<tr>
<td>63739028110</td>
</tr>
<tr>
<td>63739028203</td>
</tr>
<tr>
<td>63739028210</td>
</tr>
<tr>
<td>63739041910</td>
</tr>
<tr>
<td>63739042010</td>
</tr>
<tr>
<td>63739042110</td>
</tr>
<tr>
<td>63739042210</td>
</tr>
<tr>
<td>63739043510</td>
</tr>
<tr>
<td>63739043610</td>
</tr>
<tr>
<td>63739043710</td>
</tr>
<tr>
<td>63739043810</td>
</tr>
<tr>
<td>64899041801</td>
</tr>
<tr>
<td>64899044901</td>
</tr>
<tr>
<td>64899045801</td>
</tr>
<tr>
<td>64915014160</td>
</tr>
<tr>
<td>64980010301</td>
</tr>
<tr>
<td>65162003210</td>
</tr>
<tr>
<td>65162003230</td>
</tr>
<tr>
<td>65162041810</td>
</tr>
<tr>
<td>65162041811</td>
</tr>
<tr>
<td>65162042010</td>
</tr>
<tr>
<td>65162042110</td>
</tr>
<tr>
<td>65224058001</td>
</tr>
<tr>
<td>65243006515</td>
</tr>
<tr>
<td>65243006545</td>
</tr>
<tr>
<td>65243008215</td>
</tr>
<tr>
<td>65243008245</td>
</tr>
<tr>
<td>65243012745</td>
</tr>
<tr>
<td>65243020206</td>
</tr>
<tr>
<td>65243020209</td>
</tr>
<tr>
<td>65243028409</td>
</tr>
<tr>
<td>65243028418</td>
</tr>
<tr>
<td>65243034815</td>
</tr>
<tr>
<td>65243034845</td>
</tr>
<tr>
<td>65243034915</td>
</tr>
<tr>
<td>65243034945</td>
</tr>
<tr>
<td>65243035045</td>
</tr>
<tr>
<td>65243035203</td>
</tr>
<tr>
<td>65243035209</td>
</tr>
<tr>
<td>65243035245</td>
</tr>
<tr>
<td>65243035609</td>
</tr>
<tr>
<td>65243035709</td>
</tr>
<tr>
<td>Numerator</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>65243036045</td>
</tr>
<tr>
<td>65243036245</td>
</tr>
<tr>
<td>65243036709</td>
</tr>
<tr>
<td>65597070118</td>
</tr>
<tr>
<td>65597090230</td>
</tr>
<tr>
<td>65726040125</td>
</tr>
<tr>
<td>65726040325</td>
</tr>
<tr>
<td>65726042427</td>
</tr>
<tr>
<td>65726042532</td>
</tr>
<tr>
<td>65779041040</td>
</tr>
<tr>
<td>65862005190</td>
</tr>
<tr>
<td>65862005226</td>
</tr>
<tr>
<td>65862005249</td>
</tr>
<tr>
<td>65862005322</td>
</tr>
<tr>
<td>65862005390</td>
</tr>
<tr>
<td>65862005430</td>
</tr>
<tr>
<td>65862005490</td>
</tr>
<tr>
<td>66105097903</td>
</tr>
<tr>
<td>66116023830</td>
</tr>
<tr>
<td>66116027730</td>
</tr>
<tr>
<td>66116056130</td>
</tr>
<tr>
<td>66267056160</td>
</tr>
<tr>
<td>66336031030</td>
</tr>
<tr>
<td>66336036760</td>
</tr>
<tr>
<td>66336041230</td>
</tr>
<tr>
<td>66336095330</td>
</tr>
</tbody>
</table>
Numerator *LIPID LOWERING AGENTS 66336095430
Numerator *LIPID LOWERING AGENTS 66336095490
Numerator *LIPID LOWERING AGENTS 66336098630
Numerator *LIPID LOWERING AGENTS 665820311101
Numerator *LIPID LOWERING AGENTS 665820311128
Numerator *LIPID LOWERING AGENTS 665820311131
Numerator *LIPID LOWERING AGENTS 665820311154
Numerator *LIPID LOWERING AGENTS 665820311182
Numerator *LIPID LOWERING AGENTS 665820312128
Numerator *LIPID LOWERING AGENTS 665820312129
Numerator *LIPID LOWERING AGENTS 665820312131
Numerator *LIPID LOWERING AGENTS 665820312154
Numerator *LIPID LOWERING AGENTS 665820312182
Numerator *LIPID LOWERING AGENTS 665820312187
Numerator *LIPID LOWERING AGENTS 665820313131
Numerator *LIPID LOWERING AGENTS 665820313152
Numerator *LIPID LOWERING AGENTS 665820313154
Numerator *LIPID LOWERING AGENTS 665820313174
Numerator *LIPID LOWERING AGENTS 665820313186
Numerator *LIPID LOWERING AGENTS 665820313150
Numerator *LIPID LOWERING AGENTS 665820313151
Numerator *LIPID LOWERING AGENTS 665820313152
Numerator *LIPID LOWERING AGENTS 665820313154
Numerator *LIPID LOWERING AGENTS 665820313156
Numerator *LIPID LOWERING AGENTS 665820313158
Numerator *LIPID LOWERING AGENTS 665820313162
Numerator *LIPID LOWERING AGENTS 6658203131474
Numerator *LIPID LOWERING AGENTS 6658203131476
Numerator *LIPID LOWERING AGENTS 66689013720
Numerator *LIPID LOWERING AGENTS 66689013730
Numerator *LIPID LOWERING AGENTS 66689014720
Numerator *LIPID LOWERING AGENTS 66689014730
Numerator *LIPID LOWERING AGENTS 67253074106
Numerator *LIPID LOWERING AGENTS 67253074150
Numerator *LIPID LOWERING AGENTS 67253074155
Numerator *LIPID LOWERING AGENTS 67253074160
Numerator *LIPID LOWERING AGENTS 67253074165
Numerator *LIPID LOWERING AGENTS 67253074170
Numerator *LIPID LOWERING AGENTS 67263004890
Numerator *LIPID LOWERING AGENTS 67263026790
Numerator *LIPID LOWERING AGENTS 67263044001
Numerator *LIPID LOWERING AGENTS 67263054101
Numerator *LIPID LOWERING AGENTS 67544005015
Numerator *LIPID LOWERING AGENTS 67544005030
Numerator *LIPID LOWERING AGENTS 67544005045
Numerator *LIPID LOWERING AGENTS 67544005053
Numerator *LIPID LOWERING AGENTS 67544005060
Numerator *LIPID LOWERING AGENTS 67544005115
Numerator *LIPID LOWERING AGENTS 67544005116
Numerator *LIPID LOWERING AGENTS 67544005145
Numerator *LIPID LOWERING AGENTS 67544005153
Numerator *LIPID LOWERING AGENTS 67544006015
Numerator *LIPID LOWERING AGENTS 67544006045
Numerator *LIPID LOWERING AGENTS 67544006060
Numerator *LIPID LOWERING AGENTS 67544008115
<table>
<thead>
<tr>
<th>Numerator</th>
<th>LIPID LOWERING AGENTS</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544100315</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544100345</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544100353</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544102999</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103099</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103215</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103245</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103282</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103299</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103398</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103760</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103780</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544103793</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544111160</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544114760</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125415</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125445</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125515</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125530</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125545</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125560</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125615</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125630</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125645</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125745</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544125760</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544132515</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67544132545</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67707004330</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67707013099</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67801030103</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>67801031403</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68016002008</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68016002059</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68016002273</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68030861501</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68071026330</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68071043330</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68071078430</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013101</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013111</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013201</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013211</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013301</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084013311</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016101</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016111</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016201</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016211</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016301</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016311</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68084016401</td>
</tr>
<tr>
<td>Numerator</td>
<td>*LIPID LOWERING AGENTS</td>
<td>Value</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084016501</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084016511</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018601</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018611</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018701</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018711</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018801</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084018811</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084032811</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084032821</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084032911</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084032921</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084047301</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68084047311</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115015360</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115015390</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115015397</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115021830</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115021930</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115021960</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115049430</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115049460</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115064697</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115064800</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115065800</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115066490</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115066815</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115066830</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115066890</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115067230</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115072030</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115075930</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115077790</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115080090</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115082130</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115083630</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68115083690</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046701</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046703</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046707</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046801</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046803</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046805</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046807</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046901</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046903</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046905</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180046907</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047801</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047802</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047803</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047901</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047902</td>
</tr>
<tr>
<td>627</td>
<td>*LIPID LOWERING AGENTS</td>
<td>68180047903</td>
</tr>
</tbody>
</table>
627 Numerator *LIPID LOWERING AGENTS 68180048001
627 Numerator *LIPID LOWERING AGENTS 68180048002
627 Numerator *LIPID LOWERING AGENTS 68180048003
627 Numerator *LIPID LOWERING AGENTS 68180048101
627 Numerator *LIPID LOWERING AGENTS 68180048102
627 Numerator *LIPID LOWERING AGENTS 68180048103
627 Numerator *LIPID LOWERING AGENTS 68180048206
627 Numerator *LIPID LOWERING AGENTS 68180048209
627 Numerator *LIPID LOWERING AGENTS 68180048502
627 Numerator *LIPID LOWERING AGENTS 68180048509
627 Numerator *LIPID LOWERING AGENTS 68180048602
627 Numerator *LIPID LOWERING AGENTS 68180048609
627 Numerator *LIPID LOWERING AGENTS 68180048702
627 Numerator *LIPID LOWERING AGENTS 68180048709
627 Numerator *LIPID LOWERING AGENTS 68180048802
627 Numerator *LIPID LOWERING AGENTS 68180048809
627 Numerator *LIPID LOWERING AGENTS 68258104001
627 Numerator *LIPID LOWERING AGENTS 68258105701
627 Numerator *LIPID LOWERING AGENTS 68258106701
627 Numerator *LIPID LOWERING AGENTS 6825860009
627 Numerator *LIPID LOWERING AGENTS 68258600109
627 Numerator *LIPID LOWERING AGENTS 68258600209
627 Numerator *LIPID LOWERING AGENTS 68258900101
627 Numerator *LIPID LOWERING AGENTS 68258909301
627 Numerator *LIPID LOWERING AGENTS 68258909401
627 Numerator *LIPID LOWERING AGENTS 68258912801
627 Numerator *LIPID LOWERING AGENTS 68258915401
627 Numerator *LIPID LOWERING AGENTS 68382006505
627 Numerator *LIPID LOWERING AGENTS 68382006506
627 Numerator *LIPID LOWERING AGENTS 68382006510
627 Numerator *LIPID LOWERING AGENTS 68382006514
627 Numerator *LIPID LOWERING AGENTS 68382006516
627 Numerator *LIPID LOWERING AGENTS 68382006605
627 Numerator *LIPID LOWERING AGENTS 68382006606
627 Numerator *LIPID LOWERING AGENTS 68382006610
627 Numerator *LIPID LOWERING AGENTS 68382006614
627 Numerator *LIPID LOWERING AGENTS 68382006616
627 Numerator *LIPID LOWERING AGENTS 68382006624
627 Numerator *LIPID LOWERING AGENTS 683820066705
627 Numerator *LIPID LOWERING AGENTS 683820066706
627 Numerator *LIPID LOWERING AGENTS 683820066710
627 Numerator *LIPID LOWERING AGENTS 683820066714
627 Numerator *LIPID LOWERING AGENTS 683820066716
627 Numerator *LIPID LOWERING AGENTS 68382006724
627 Numerator *LIPID LOWERING AGENTS 68382006805
627 Numerator *LIPID LOWERING AGENTS 68382006806
627 Numerator *LIPID LOWERING AGENTS 68382006810
627 Numerator *LIPID LOWERING AGENTS 68382006814
627 Numerator *LIPID LOWERING AGENTS 68382006816
627 Numerator *LIPID LOWERING AGENTS 68382006840
627 Numerator *LIPID LOWERING AGENTS 68382006905
627 Numerator *LIPID LOWERING AGENTS 68382006906
627 Numerator *LIPID LOWERING AGENTS 68382006910
627 Numerator *LIPID LOWERING AGENTS 68382006914
627 Numerator *LIPID LOWERING AGENTS 68382006916
<table>
<thead>
<tr>
<th>Numerator</th>
<th>LIPID LOWERING AGENTS</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838207005</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838207105</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838207205</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838207305</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838207316</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68382010005</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68382010014</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>6838201015</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019505</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019590</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019605</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019690</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019705</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019790</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019805</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68462019890</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68645026254</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>68645026254</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312000720</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312001480</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312001810</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312003822</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312005441</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312005800</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312007200</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>74312007500</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273042410</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273042705</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273072705</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273072790</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273072910</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273072920</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>77273094890</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854002893</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854001007</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854001008</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854001097</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854011893</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020125</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020130</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020140</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020311</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020312</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020560</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>79854020983</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>803285586727</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>803285587204</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701000814</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701008144</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701025823</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701034323</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701040312</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701040841</td>
</tr>
<tr>
<td>627</td>
<td>LIPID LOWERING AGENTS</td>
<td>87701071245</td>
</tr>
<tr>
<td>Numerator</td>
<td>LIPID LOWERING AGENTS</td>
<td>Denominator</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>87701071357</td>
<td></td>
<td></td>
</tr>
<tr>
<td>87701071360</td>
<td></td>
<td></td>
</tr>
<tr>
<td>87701086735</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89269045242</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89269045401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89269045402</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89269045403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89269045405</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91899042472</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91899045365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96295011205</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96295011249</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96295011767</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97807041039</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97807041040</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97807041087</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td>NIACIN 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 10 MG/ML AMPUL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 10 MG/ML AMPUL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIVALO 1 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIVALO 2 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIVALO 4 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 10 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 10 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 40 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTO-CHOL CAPSULE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTO-CHOL CAPSULE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTO-CHOL CAPSULE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 25 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 10 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 10 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVIGARD PAC 81-20 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVIGARD PAC 325-20 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVIGARD PAC 81-40 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVIGARD PAC 325-40 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 81-80 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 325-80 MG TAB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 40 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 40 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAVACHOL 80 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 80 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 80 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 80 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 80 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 5 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 10 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZOCOR 20 MG TABLET</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 40 MG TABLET
MEVACOR 40 MG TABLET
MEVACOR 40 MG TABLET
MEVACOR 40 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
COLESTID GRANULES PACKET
COLESTID GRANULES
COLESTID GRANULES PACKET
COLESTID GRANULES
COLESTID FLAVORED GRANULES
COLESTID FLAVORED GRANULES
COLESTID 1 GM TABLET
QUESTRA
QUESTRA LIGHT PACKET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
BAYCOL 0.2 MG TABLET
BAYCOL 0.2 MG TABLET
BAYCOL 0.3 MG TABLET
BAYCOL 0.3 MG TABLET
BAYCOL 0.4 MG TABLET
BAYCOL 0.4 MG TABLET
BAYCOL 0.4 MG TABLET
BAYCOL 0.8 MG TABLET
BAYCOL 0.8 MG TABLET
ATROMID-S 500 MG CAPSULE
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOCHOLEST PACKET
LOCHOLEST POWDER
LOCHOLEST LIGHT PACKET
LOCHOLEST LIGHT POWDER
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE LIGHT PACKET
CHOLESTYRAMINE LIGHT POWDER
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
CADUET 5 MG-10 MG TABLET
CADUET 10 MG-10 MG TABLET
CADUET 5 MG-20 MG TABLET
CADUET 10 MG-20 MG TABLET
CADUET 5 MG-40 MG TABLET
CADUET 10 MG-40 MG TABLET
CADUET 5 MG-80 MG TABLET
CADUET 10 MG-80 MG TABLET
CADUET 2.5 MG-10 MG TABLET
CADUET 2.5 MG-20 MG TABLET
CADUET 2.5 MG-40 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LOPID 300 MG CAPSULE
LOPID 300 MG CAPSULE
LOPID 600 MG TABLET
LOPID 600 MG TABLET
LOPID 600 MG TABLET
CHOLYBAR CARAMEL
CHOLYBAR RASPBERRY
ADVICOR 500 MG-20 MG TABLET
ADVICOR 1,000 MG-20 MG TABLET
ADVICOR 1,000 MG-40 MG TABLET
ADVICOR 750 MG-20 MG TABLET
NIASPAN 500 MG TABLET ER
NIASPAN 750 MG TABLET ER
NIASPAN 1,000 MG TABLET ER
SIMCOR 500-20 MG TABLET
SIMCOR 750-20 MG TABLET
SIMCOR 1,000-20 MG TABLET
SIMCOR 1,000-20 MG TABLET
SIMCOR 1,000-40 MG TABLET
SIMCOR 500-40 MG TABLET
TRICOR 54 MG TABLET
TRICOR 160 MG TABLET
TRICOR 67 MG CAPSULE
TRICOR 48 MG TABLET
TRICOR 145 MG TABLET
TRICOR 200 MG CAPSULE
TRICOR 134 MG CAPSULE
TRILIPIX DR 135 MG CAPSULE
TRILIPIX 45 MG CAPSULE DR
NICOBID TEMPULE 125 MG
NICOBID TEMPULE 125 MG
NICOBID TEMPULE 250 MG
NICOBID TEMPULE 250 MG
NICOBID TEMPULE 500 MG
NICOBID TEMPULE 500 MG
NICOLAR 500 MG TABLET
LESCOL 20 MG CAPSULE
LESCOL 20 MG CAPSULE
LESCOL 40 MG CAPSULE
LESCOL 40 MG CAPSULE
LESCOL XL 80 MG TABLET
LESCOL XL 80 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
QUESTRAN PACKET
QUESTRAN POWDER
QUESTRAN PACKET
QUESTRAN POWDER
QUESTRAN PACKET
QUESTRAN LIGHT POWDER
QUESTRAN LIGHT PACKET
QUESTRAN 1 GM TABLET
QUESTRAN LIGHT POWDER
NICO-400 PLATEAU CAPS
CLOFIBRATE 500 MG CAPSULE
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
COLESTIPOL HCL 1 GM TABLET
COLESTIPOL HCL GRANULES PACKET
COLESTIPOL HCL GRANULES PACKET
COLESTIPOL HCL GRANULES
FENOFIBRATE 54 MG TABLET
FENOFIBRATE 160 MG TABLET
FENOFIBRATE 160 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
MAX EPA MARINE LIPID CAP
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
OMEGA-3 CAPSULE
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
MAX-EPA CAPSULE
NIACIN 25 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
LOVAZA 1 GM CAPSULE
LOVAZA 1 GM CAPSULE
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
FISH OIL CONC 1,000 MG CAP
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
CLOFIBRATE 500 MG CAPSULE
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 125 MG CAPLET SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN W/RICE BRAN TAB SA
NIACIN 750 MG CAPLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 500 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
CHOLESTYRAMINE PACKET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
CHOLESTYRAMINE LIGHT POWDER
CHOLESTYRAMINE LIGHT PACKET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE PACKET
NICOCAP 400 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 25 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
TEGA-SPAN 400 MG CAPSULE SA
TEGA-SPAN 400 MG CAPSULE SA
TEGA SPAN-250 CAPSULE SA
TEGA SPAN-250 CAPSULE SA
TEGA SPAN 250 MG CAPSULE SA
TEGA SPAN 250 MG CAPSULE SA
TEGA SPAN-400 CAPSULE SA
TEGA SPAN-400 CAPSULE SA
TEGA SPAN-125 CAPSULE SA
TEGA SPAN-125 CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
CLOFIBRATE 500 MG CAPSULE
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
NIACIN 500 MG TABLET
PREVALITE POWDER
PREVALITE PACKET
PREVALITE PACKET
PREVALITE PACKET
NIACOR-B3 500 MG TABLET
GEMFIBROZIL 600 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG CAPSULE SA
NIACIN 100 MG/ML VIAL
NIACELS 400 MG CAPSULE SA
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SPAN NIACIN 150 MG TABLET SA</td>
<td></td>
</tr>
<tr>
<td>SPAN NIACIN 150 MG TABLET SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 400 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG/ML VIAL</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 25 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 25 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SEA-OMEGA 70 SOFTGEL</td>
<td></td>
</tr>
<tr>
<td>CLOFIBRATE 500 MG CAPSULE</td>
<td></td>
</tr>
<tr>
<td>CLOFIBRATE 500 MG CAPSULE</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 50 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 125 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 125 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 250 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 250 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 400 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 400 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG CAPSULE SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 25 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>CHOLESTYRAMINE LIGHT PACKET</td>
<td></td>
</tr>
<tr>
<td>CHOLESTYRAMINE LIGHT POWDER</td>
<td></td>
</tr>
<tr>
<td>NIACIN 500 MG TABLET SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 750 MG TABLET SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 1,000 MG TABLET SA</td>
<td></td>
</tr>
<tr>
<td>NIACIN 750 MG TABLET SA</td>
<td></td>
</tr>
</tbody>
</table>
NIACIN W/OAT BRAN TABLET
NIACIN 1,000 MG TABLET SA
NIACIN 500 MG TABLET
NIACIN 25 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
COLESTRIN CAPSULE
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
CLOFIBRATE 500 MG CAPSULE
NIACIN 125 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 750 MG CAPLET SA
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
OMEGA VITE APPROGEL
NIACIN 500 MG CAPLET SA
NIACIN 250 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
FISH OIL CONCENTRATE CAP
CLOFIBRATE 500 MG CAPSULE
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN TD 125 MG CAPSULE SA
NIACIN TD 250 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NICOTYM 400 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SR
NIACIN 250 MG CAPSULE SR
SUPER EPA-300 CAPSULE
SUPER EPA-500 CAPSULE
CLOFIBRATE 500 MG CAPSULE
NIACIN 400 MG CAPSULE SR
UNI-KHOL 100 MG CAPSULE
NIACIN 500 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 750 MG CAPLET SA
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 25 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
CLOFIBRATE 500 MG CAPSULE
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
SUPER-EPA:CAPSULE
SUPER-EPA:CAPSULE
SUPER-EPA:CAPSULE
CLOFIBRATE 500 MG CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
CLOFIBRATE 500 MG CAPSULE
FISH OIL CONCENTRATE CAP
NIACIN 125 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 750 MG CAPLET SA
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 50 MG CAPLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG CAPLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
CLOFIBRATE 500 MG CAPSULE
FISH OIL 1,000 MG CAPSULE
EPA-CON CAPSULE
FISH OIL 500 MG CAPSULE
NIACIN 500 MG CAPLET SA
NIACIN 500 MG CAPLET SA
NIACIN 750 MG CAPLET SA
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE LIGHT POWDER
CHOLESTYRAMINE LIGHT PACKET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
FISH OIL 500 MG SOFTGEL
FISH OIL 1,000 MG SOFTGEL
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
OSCO NIACIN 50 MG TABLET
OSCO NIACIN 100 MG TABLET
OSCO NIACIN 100 MG TABLET
SAV-ON NIACIN 50 MG TABLET
SAV-ON NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 100 MG TABLET
EPA-CHOL CAPSULE
MEGA 3 FISH OIL CONC CAP
OMEGA 3 NAT FISH OIL CAP
SUPREPA 1000 SOFTGEL
SUPREPA 1000 SOFTGEL
SUPREPA 1200 SOFTGEL
SUPREPA 1200 SOFTGEL
SALMON OIL 1,000 MG SOFTGEL
FORMULA 3/6/9 SOFTGEL
FORMULA 3/6/9 SOFTGEL
SUPREPA 2000 750 MG SOFTGEL
SUPREPA 2000 750 MG SOFTGEL
SUPREPA 2000 750 MG SOFTGEL
NEW ENERGY SOFTGEL
NIACIN 100 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 500 MG TABLET SA
SM FISH OIL CONCENTRATE SFG
SUNMARK NIACIN 250 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NA-500 T.R. CAPSULE
NIACIN 100 MG TABLET
NIACIN 500 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 500 MG TABLET
NIACIN 250 MG CAPSULE SA
RA NIACIN 100 MG TABLET
RA FISH OIL 1,000 MG SOFTGEL
RA NIACIN 50 MG TABLET
RA NIACIN 100 MG TABLET
RA NAT FISH OIL CONC CAP
RA NIACIN 100 MG TABLET
RA NIACIN 250 MG TABLET
RA FISH OIL 1,000 MG SOFTGEL
FISH OIL 1,000 MG SOFTGEL
RA NIACIN 500 MG TABLET
RA FISH OIL 1,000 MG SOFTGEL
RA FISH OIL 1,000 MG SOFTGEL
RA FISH OIL 1,000 MG SOFTGEL
RA NIACIN 100 MG TABLET
RA FISH OIL 1,000 MG SOFTGEL
FISH OIL 1,000 MG SOFTGEL
SUPER OMEGA-3 SOFTGEL
FISH OIL 1,000 MG SOFTGEL
NIACIN 500 MG CAPSULE
OMEGA 3-6-9 1,200 MG SOFTGEL
NIACIN FLUSH FREE 750 MG CAP
CLOFIBRATE 500 MG CAPSULE
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 125 MG CAPSULE SA
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
MAX EPA 1,000 MG CAPSULE
CLOFIBRATE 500 MG CAPSULE
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN POWDER
NIACIN POWDER
NIACIN POWDER
ECK NIACIN 100 MG TABLET
ECK NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
LIPITOR 40 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 20 MG TABLET
VYTORIN 10-20 MG TABLET
VYTORIN 10-40 MG TABLET
NIACIN 500 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
EPA 1,000 MG CAPSULE
NIACIN 500 MG TABLET SA
NIACIN 250 MG TABLET SA
SUPER TWIN EPA-DHA 1,250 MG
OMEGA-3 1,000 MG SOFTGEL
ANTARA 43 MG CAPSULE
ANTARA 130 MG CAPSULE
ANTARA 130 MG CAPSULE
ENDUR-ACIN 500 MG TABLET SA
ENDUR-ACIN 250 MG TABLET SR
ENDUR-ACIN 500 MG TABLET SR
FISH OIL 1,000 MG SOFTGEL
NIACIN 100 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVAZA 1 GM CAPSULE
LOVAZA 1 GM CAPSULE
LOVAZA 1 GM CAPSULE
PRAVASTATIN SODIUM 40 MG TAB
NIASPAN 750 MG TABLET ER
NIASPAN 1,000 MG TABLET ER
CRESTOR 40 MG TABLET
CRESTOR 5 MG TABLET
SIMVASTATIN 80 MG TABLET
FENOFIBRATE 160 MG TABLET
SIMVASTATIN 10 MG TABLET
CLOFIBRATE 500 MG CAPSULE
NIACIN 100 MG TABLET
FISH OIL 300 MG SOFTGEL
FISH OIL EXTRA STRENGTH SFTGEL
FISH OIL 1,000 MG EC SOFTGEL
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE LIGHT POWDER
CHOLESTYRAMINE LIGHT PACKET
GEMFIBROZIL POWDER
GEMFIBROZIL POWDER
GEMFIBROZIL POWDER
GEMFIBROZIL POWDER
GEMFIBROZIL POWDER
OMEGA-3 1,000 MG SOFTGEL
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG TABLET
NIACIN 100 MG TABLET
FISH OIL 1,000 MG SOFTGEL
TREASURY NAT FISH OIL CAP
TREASURY Niacin 100 MG TAB
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 50 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 50 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 50 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 100 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA

SUNMARK Niacin 250 MG TABLET
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
NIACIN POWDER
NIACIN POWDER
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
FISH OIL 1,000 MG SOFTGEL
FISH OIL EXTRA STRENGTH SOFTGL
COQ-10 & FISH OIL SOFTGEL
NIACIN 250 MG SA TABLET
NIACIN 500 MG SA TABLET
NIACIN 100 MG TAB SYNTHETIC
NIACIN 100 MG TAB SYNTHETIC
NIACIN 250 MG SA TABLET
NIACIN 500 MG SA TABLET
OMEGA 3 FISH OIL CONC CAP
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG CAPSULE SA
NIACIN 500 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
CLOFIBRATE 500 MG CAPSULE
CLOFIBRATE 500 MG CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
TRICOL CAPSULE
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE LIGHT PACKET
CHOLESTYRAMINE LIGHT POWDER
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
QUESTRAN PACKET
QUESTRAN POWDER
QUESTRAN LIGHT PACKET
QUESTRAN LIGHT POWDER
QUESTRAN PACKET
QUESTRAN POWDER
QUESTRAN LIGHT PACKET
QUESTRAN LIGHT POWDER
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 10 MG TABLET
ZOCOR 20 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
NIASPAN 500 MG TABLET ER
ZETIA 10 MG TABLET
ZETIA 10 MG TABLET
ZOCOR 40 MG TABLET
NIACIN 1,000 MG TABLET SA
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
VYTORIN 10-20 MG TABLET
VYTORIN 10-40 MG TABLET
WELCHOL 625 MG TABLET
CADUET 5 MG-10 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPLET SA
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPLET SA
NIACIN 250 MG CAPLET SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 500 MG CAPLET SA
NIACIN 750 MG CAPLET SA
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
<table>
<thead>
<tr>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niacin 50 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>CVS Niacin 50 Mg Tablet</td>
</tr>
<tr>
<td>CVS Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>CVS Fish Oil Concentrate Cp</td>
</tr>
<tr>
<td>CVS Fish Oil 1,000 Mg Softgel</td>
</tr>
<tr>
<td>Niacin 125 Mg Capsule Sa</td>
</tr>
<tr>
<td>Niacin 250 Mg Capsule Sa</td>
</tr>
<tr>
<td>Gemfibrozil 600 Mg Tablet</td>
</tr>
<tr>
<td>Gemfibrozil 600 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 25 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 50 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 50 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>Niacin 100 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Pravastatin Sodium 20 Mg Tab</td>
</tr>
<tr>
<td>Pravastatin Sodium 20 Mg Tab</td>
</tr>
<tr>
<td>Pravastatin Sodium 40 Mg Tab</td>
</tr>
<tr>
<td>Pravastatin Sodium 40 Mg Tab</td>
</tr>
<tr>
<td>Gemfibrozil 600 Mg Tablet</td>
</tr>
<tr>
<td>Gemfibrozil 600 Mg Tablet</td>
</tr>
<tr>
<td>Gemfibrozil 600 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 5 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Lovastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 5 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 10 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 20 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 40 Mg Tablet</td>
</tr>
<tr>
<td>Simvastatin 80 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 10 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 10 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 10 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 10 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 20 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 20 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 20 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 20 Mg Tablet</td>
</tr>
<tr>
<td>Lipitor 40 Mg Tablet</td>
</tr>
</tbody>
</table>
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 80 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
CRESTOR 5 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 20 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
CLOFIBRATE 500 MG CAPSULE
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
CLOFIBRATE LIQUID
NIACIN POWDER
NIACIN POWDER
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 100 MG TABLET
CHOLESTYRAMINE RESIN POWDER
GEMFIBROZIL POWDER
EPAFROL CAPSULE
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
F V NIACIN 100 MG TABLET
F V FISH OIL CONCENTRATE CAP
H M FISH OIL CONCENTRATE CAP
H M NIACIN 100 MG TABLET
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
CLOFIBRATE 500 MG CAPSULE
NIACIN TD 125 MG CAPSULE SA
NIACIN TD 250 MG CAPSULE SA
NIACIN TD 250 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
CLOFIBRATE 500 MG CAPSULE
GEMFIBROZIL 600 MG TABLET
HM NIACIN 100 MG TABLET
NIACIN 25 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NICO-400 CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
FENOGlide 40 MG TABLET
FENOGlide 120 MG TABLET
FP FISH OIL CONC CAPSULE
FIP NIACIN 250 MG CAP SA
FP NIACIN 100 MG TABLET
LIPITOR 40 MG TABLET
ZOCOR 40 MG TABLET
LOVASTATIN 20 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
SIMVASTATIN 40 MG TABLET
LOVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
NICOTINIC ACID 500 MG CAP SA
NICOTINIC ACID 100 MG TABLET
B3-50 TABLET
SAM-300 CAPSULE
B3-500-GR TABLET SA
NIAPLUS 400 MG CAPSULE SA
SOF-GEL EFA CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
FENOFIBRIC ACID 35 MG TABLET
FENOFIBRIC ACID 105 MG TABLET
FENOFIBRIC ACID 105 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
NIACIN 500 MG CAPSULE SA
SUPER EPA-500 CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
MARINE LIPID CONC CAPSULE
LOPID 600 MG TABLET
MEVACOR 20 MG TABLET
CLOFIBRATE 500 MG CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 400 MG CAPSULE SA
NIATAB 500 MG TABLET SA
CLOFIBRATE 500 MG CAPSULE
OMEGA-3 1,000 MG SOFTGEL
OMEGA 3 1,000 MG SOFTGEL
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 10 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 10 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
CLOFIBRATE 500 MG CAPSULE
NICOBID 250 MG TEMPULE
NICOBID 250 MG TEMPULE
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
ATROMID-S 500 MG CAPSULE
ATROMID-S 500 MG CAPSULE
LOPID 300 MG CAPSULE
LOPID 300 MG CAPSULE
NIACIN 125 MG CAPSULE SA
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
QUESTRAN PACKET
QUESTRAN PACKET
QUESTRAN PACKET
QUESTRAN POWDER
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
NIACIN 50 MG TABLET
COLESTID GRANULES
CHOLYBAR RASPBERRY
CHOLYBAR CARAMEL
NIACIN 125 MG CAPSULE SA
NIACIN 125 MG CAPSULE SA
LOPID 600 MG TABLET
LOPID 600 MG TABLET
LOPID 600 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
MEVACOR 40 MG TABLET
MEVACOR 40 MG TABLET
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
NIACIN 250 MG CAPSULE SA
QUESTRAN LIGHT POWDER
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 20 MG TABLET
LESCOL 20 MG CAPSULE
PRAVACHOL 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 20 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
MEVACOR 10 MG TABLET
BAYCOL 0.3 MG TABLET
PRAVACHOL 40 MG TABLET
CHOLESTYRAMINE LIGHT POWDER
CHOLESTYRAMINE PACKET
TRICOR 67 MG CAPSULE
LESCOL 40 MG CAPSULE
LESCOL 40 MG CAPSULE
NIASPAN 750 MG TABLET SA
CHOLESTYRAMINE LIGHT POWDER
NIACINOL 500 MG CAPSULE
BAYCOL 0.4 MG TABLET
QUESTRAN LIGHT POWDER
BAYCOL 0.8 MG TABLET
NIASPAN 1,000 MG TABLET ER
NIASPAN 500 MG TABLET SA
NIASPAN 500 MG TABLET SA
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LIPITOR 80 MG TABLET
NIACIN 500 MG CAPLET SA
ZETIA 10 MG TABLET
LESCOL XL 80 MG TABLET SA
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
ZOCOR 80 MG TABLET
VYTORIN 10-40 MG TABLET
CRESTOR 20 MG TABLET
CADUET 5 MG-10 MG TABLET
CRESTOR 5 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
VYTORIN 10-20 MG TABLET
VYTORIN 10-10 MG TABLET
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
CADUET 10 MG-10 MG TABLET
OMACOR CAPSULE
LOVAZA 1 GM CAPSULE
CADUET 10 MG-20 MG TABLET
FISH OIL 1,000 MG CAPSULE
CADUET 10 MG-40 MG TABLET
SIMVASTATIN 80 MG TABLET
NIACIN 250 MG CAPSULE SA
MEVACOR 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVACHOL 10 MG TABLET
OMEGA-3 1,000 MG SOFTGEL
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET SA
ODASPIN 1,000 MG TABLET ER
ODASPIN 1,000 MG TABLET ER
ODASPIN 1,000 MG TABLET ER
ODASPIN 1,000 MG TABLET ER
NIASPAN 1,000 MG TABLET ER
NIASPAN ER 1,000 MG TABLET
COLESTIPOL HCL 1 GM TABLET
COLESTIPOL HCL 1 GM TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 20 MG TABLET
MEVACOR 40 MG TABLET
MEVACOR 40 MG TABLET
CADUET 5 MG-20 MG TABLET
CADUET 5 MG-20 MG TABLET
QUESTRAN POWDER
LOPID 600 MG TABLET
LOPID 600 MG TABLET
NIACIN 50 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 250 MG CAPSULE SA
CRESTOR 40 MG TABLET
CRESTOR 40 MG TABLET
MEVACOR 10 MG TABLET
NIACIN 100 MG TABLET
NIACIN 100 MG TABLET
PRAVACHOL 10 MG TABLET
PRAVACHOL 10 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
QUESTRAN PACKET
QUESTRAN LIGHT PACKET
COLESTID GRANULES
COLESTID FLAVORED GRANULES
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
PRAVACHOL 40 MG TABLET
PRAVACHOL 40 MG TABLET
PRAVACHOL 40 MG TABLET
CADUET 5 MG-10 MG TABLET
CADUET 5 MG-10 MG TABLET
LESCOL 20 MG CAPSULE
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 20 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 80 MG TABLET
ZOCOR 80 MG TABLET
LESCOL 40 MG CAPSULE
LESCOL 40 MG CAPSULE
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 40 MG TABLET
BAYCOL 0.4 MG TABLET
WELCHOL 625 MG TABLET
WELCHOL 625 MG TABLET
WELCHOL 625 MG TABLET
WELCHOL 625 MG TABLET
TRICOR 200 MG CAPSULE
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
TRICOR 54 MG TABLET
TRICOR 160 MG TABLET
LESCOL XL 80 MG TABLET
PRAVACHOL 80 MG TABLET
ZETIA 10 MG TABLET
ZETIA 10 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
ADVICOR 500 MG-20 MG TABLET
ADVICOR 500 MG-20 MG TABLET
ADVICOR 500 MG-20 MG TABLET
CHOLESTERYRAMINE POWDER
CHOLESTERYRAMINE PACKET
NIASPAN 750 MG TABLET ER
NIASPAN 750 MG TABLET ER
NIASPAN 750 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN ER 500 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
ADVICOR 750 MG-20 MG TABLET
ADVICOR 750 MG-20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
ADVICOR 1,000 MG-20 MG TABLET
FISH OIL 1,000 MG CAPSULE
CADUET 5 MG-40 MG TABLET
NIACIN TD 125 MG CAPSULE SA
VYTORIN 10-20 MG TABLET
VYTORIN 10-20 MG TABLET
VYTORIN 10-20 MG TABLET
VYTORIN 10-40 MG TABLET
VYTORIN 10-40 MG TABLET
CADUET 10 MG-40 MG TABLET
CADUET 10 MG-40 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
CADUET 10 MG-20 MG TABLET
CADUET 10 MG-20 MG TABLET
TRICOR 48 MG TABLET
TRICOR 48 MG TABLET
VYTORIN 10-10 MG TABLET
VYTORIN 10-80 MG TABLET
VYTORIN 10-80 MG TABLET
CRESTOR 5 MG TABLET
CRESTOR 5 MG TABLET
ALTOPREV 60 MG TABLET
CADUET 5 MG-80 MG TABLET
OMACOR CAPSULE
ANTARA 130 MG CAPSULE
LOFIBRA 200 MG CAPSULE
LOFIBRA 200 MG CAPSULE
ALTOPREV 40 MG TABLET
CADUET 10 MG-80 MG TABLET
CADUET 10 MG-80 MG TABLET
CHOLESTYRAMINE LIGHT PACKET
CADUET 10 MG-10 MG TABLET
FENOFIBRATE 200 MG CAPSULE
FENOFIBRATE 200 MG CAPSULE
FENOFIBRATE 200 MG CAPSULE
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
NICOBID TEMPULE 250 MG
LESCOL 20 MG CAPSULE
NIACIN 100 MG TABLET
MEVACOR 20 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 10 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 10 MG TABLET
VYTORIN 10-40 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
NIACIN TD 250 MG CAPSULE
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
MEVACOR 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LESCOL 40 MG CAPSULE
VYTORIN 10-80 MG TABLET
MEVACOR 40 MG TABLET
NIACIN 500 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LESCOL 20 MG CAPSULE
LIPITOR 20 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 10 MG TABLET
PRAVACHOL 20 MG TABLET
PRAVACHOL 40 MG TABLET
ZOCOR 40 MG TABLET
LOVASTATIN 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 10 MG TABLET
ZETIA 10 MG TABLET
ZETIA 10 MG TABLET
TRICOR 145 MG TABLET
VYTORIN 10-20 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
LOVASTATIN 10 MG TABLET
LIPITOR 10 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
LIPITOR 40 MG TABLET
LOVASTATIN 20 MG TABLET
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE LIGHT PACKET
CHOLESTYRAMINE LIGHT POWDER
CLOFIBRATE 500 MG CAPSULE
OMEGAMINT FISH OIL 750 MG SFGL
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOFIBRA 67 MG CAPSULE
LOFIBRA 134 MG CAPSULE
LOFIBRA 200 MG CAPSULE
LOFIBRA 54 MG TABLET
LOFIBRA 160 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
LOVASTATIN 10 MG TABLET
LOVASTATIN 40 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 10 MG TABLET
LIPITOR 10 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
CRESTOR 10 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
TRICOR 145 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 20 MG TABLET
CRESTOR 40 MG TABLET
CRESTOR 40 MG TABLET
CRESTOR 40 MG TABLET
CRESTOR 40 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 10 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
PRAVACHOL 40 MG TABLET
PRAVACHOL 40 MG TABLET
ZOCOR 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 10 MG TABLET
LIPITOR 80 MG TABLET
ZETIA 10 MG TABLET
NIACIN 100 MG TABLET
EPA-DHA COMPLEX CAPSULE
EPA-DHA COMPLEX CAPSULE
NIA-BID 400 MG CAPSULE SA
NIACELS 400 MG CAPSULE SA
GEMFIBROZIL 600 MG TABLET
TRIGLIDE 50 MG TABLET
TRIGLIDE 50 MG TABLET
TRIGLIDE 160 MG TABLET
TRIGLIDE 160 MG TABLET
FENOGLIDE 40 MG TABLET
FENOGLIDE 120 MG TABLET
ALTOPREV 20 MG TABLET
ALTOPREV 40 MG TABLET
ALTOPREV 60 MG TABLET
COLESTIPOL HCL 1 GM TABLET
CHOLESTYRAMINE PACKET
CHOLESTYRAMINE POWDER
CHOLESTYRAMINE LIGHT PACKET
CHOLESTYRAMINE LIGHT POWDER
CHOLESTYRAMINE LIGHT PACKET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
LOVASTATIN 10 MG TABLET
LOVASTATIN 20 MG TABLET
<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovastatin 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Prazostatin sodium 80 mg tab</td>
<td></td>
</tr>
<tr>
<td>Prazostatin sodium 80 mg tab</td>
<td></td>
</tr>
<tr>
<td>Niaspan 500 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan 750 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan 1,000 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan starter pack</td>
<td></td>
</tr>
<tr>
<td>Advicor 500 mg-20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Advicor 750 mg-20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Advicor 1,000 mg-20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Advicor 1,000 mg-40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 500 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan 750 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan 1,000 mg tablet ER</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 100 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 50 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 500 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 60 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 60 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoprev 60 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Altoxocor 60 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 20 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil 600 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>
NIACIN POWDER
NIACIN POWDER
NIACIN POWDER
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
FENOFIBRATE 54 MG TABLET
FENOFIBRATE 160 MG TABLET
FENOFIBRATE 160 MG TABLET
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
CHOLESTYRAMINE RESIN POWDER
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LIPITOR 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
LIPITOR 80 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 80 MG TABLET
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Strength/Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMVASTATIN 80 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 20 MG TAB</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>LOVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 5 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 5 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>SIMVASTATIN 40 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>HCA Niacin 100 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>HCA Niacin 250 MG TABLET TR</td>
<td></td>
</tr>
<tr>
<td>HCA Niacin 500 MG TABLET</td>
<td></td>
</tr>
<tr>
<td>Niacinol 500 MG Capsule</td>
<td></td>
</tr>
<tr>
<td>NiaDelay 500 MG Tablet SA</td>
<td></td>
</tr>
<tr>
<td>Omega-3 1,000 MG Softgel</td>
<td></td>
</tr>
<tr>
<td>Omega-3 1,000 MG Softgel</td>
<td></td>
</tr>
<tr>
<td>Niacin 50 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 50 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 100 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 100 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niacin 250 MG Capsule SA</td>
<td></td>
</tr>
<tr>
<td>FOVEX Capsule</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 20 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 20 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Simvastatin 80 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 500 MG Tablet SA</td>
<td></td>
</tr>
<tr>
<td>Niaspan 500 MG Tablet SA</td>
<td></td>
</tr>
<tr>
<td>Niaspan 1,000 MG Tablet SA</td>
<td></td>
</tr>
<tr>
<td>Niaspan 1,000 MG Tablet SA</td>
<td></td>
</tr>
<tr>
<td>Niaspan 20 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 20 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 80 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Lovastatin 40 MG Tablet</td>
<td></td>
</tr>
<tr>
<td>Niaspan 500 MG Tablet ER</td>
<td></td>
</tr>
<tr>
<td>Niaspan 1,000 MG Tablet ER</td>
<td></td>
</tr>
</tbody>
</table>
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
WELCHOL 625 MG TABLET
WELCHOL 625 MG TABLET
WELCHOL 3.75G PACKET
ANTARA 43 MG CAPSULE
ANTARA 43 MG CAPSULE
ANTARA 130 MG CAPSULE
ANTARA 130 MG CAPSULE
OMACOR CAPSULE
OMACOR CAPSULE
LOVAZA CAPSULE
LOVAZA 1 GM CAPSULE
NIACIN 250 MG TABLET SA
NIACIN 250 MG TABLET SA
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
ZETIA 10 MG TABLET
CRESTOR 10 MG TABLET
PRAVACHOL 20 MG TABLET
LIPIITOR 10 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
GEMFIBRIZIL 600 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
PRAVASTATIN SODIUM 40 MG TAB
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 20 MG TABLET
ZOCOR 40 MG TABLET
ZOCOR 40 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
LOVASTATIN 20 MG TABLET
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 40 MG TABLET
LOVASTATIN 10 MG TABLET
LOVASTATIN 10 MG TABLET
LIPI TOR 40 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
NIASPAN 1,000 MG TABLET ER
NIASPAN 1,000 MG TABLET ER
NIASPAN 1,000 MG TABLET ER
NIASPAN 750 MG TABLET ER
NIASPAN 750 MG TABLET ER
NIASPAN 750 MG TABLET ER
ZETIA 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
NIASPAN 500 MG TABLET ER
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 80 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 10 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 10 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 20 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 20 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 40 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM 40 MG</td>
<td>Tab</td>
</tr>
<tr>
<td>FENOFIBRATE 160 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>FENOFIBRATE 160 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>FENOFIBRATE 200 MG</td>
<td>Capsule</td>
</tr>
<tr>
<td>FENOFIBRATE 200 MG</td>
<td>Capsule</td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>GEMFIBROZIL 600 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>WELCHOL 625 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>NIASPAN 500 MG</td>
<td>Tablet ER</td>
</tr>
<tr>
<td>LOVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>PRAVACHOL 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>ZOCOR 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>ZOCOR 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>ZOCOR 80 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>ZOCOR 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>ZETIA 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LIPITOR 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>LOVASTATIN 40 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 10 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
<tr>
<td>SIMVASTATIN 20 MG</td>
<td>Tablet</td>
</tr>
</tbody>
</table>
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
LIPITOR 20 MG TABLET
LOVASTATIN 20 MG TABLET
GEMFIBROZIL 600 MG TABLET
LIPITOR 10 MG TABLET
LIPITOR 20 MG TABLET
LIPITOR 40 MG TABLET
LIPITOR 80 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
PRAVACHOL 10 MG TABLET
LIPITOR 40 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 5 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 10 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 20 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 40 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
SIMVASTATIN 80 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
GEMFIBROZIL 600 MG TABLET
GEMFIBROZIL 600 MG TABLET
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 10 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 20 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 40 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
PRAVASTATIN SODIUM 80 MG TAB
SIMVASTATIN 40 MG TABLET
NIACIN 250 MG TABLET
NIACIN 100 MG TABLET
NIACIN 50 MG TABLET
FISH OIL 1,000 MG SOFTGEL
NIACIN 500 MG TABLET SA
NIACIN 250 MG CAPSULE SA
FISH OIL 1,000 MG SOFTGEL
VAYARIN CAPSULE
B-3 NIACIN 100 MG TABLET
OMEGA-3 CAPSULE
OMEGA-3 CAPSULE
OMEGA-3 CAPSULE
OMEGA-3 CAPSULE
B-3 NIACIN 500 MG CAPLET SA
OMEGA-3 1,000 MG SOFTGEL
NIACIN 250 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 100 MG TABLET
NIACIN 500 MG TABLET
OMEGA-3 1,000 MG SOFTGEL
NIACIN 50 MG TABLET
OMEGA-3 1,000 MG SOFTGEL
NIACIN 250 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET
NIACIN 500 MG TABLET
NIACIN 50 MG TABLET
NIACIN 100 MG TABLET
NIACIN 250 MG TABLET
NIACIN 500 MG TABLET SA
NIACIN 500 MG TABLET SA
BL NIACIN 250 MG TR TABLET
FISH OIL CONCENTRATE CAPS
HI-POT FISH OIL CAPSULE
GNP FISH OIL 1,000 MG SOFTGEL
GNP FISH OIL 1,000 MG SOFTGEL
GNP NIACIN 250 MG TR TABLET
BL NIACIN 250 MG TR TABLET
GNP FISH OIL 1,200 MG SOFTGEL
GNP ADVANCED EYE HEALTH SOFTGL
BL NIACIN 100 MG TABLET
BL HI-CONC OMEGA 3 CAPSULE
BL FISH OIL CONCENTRATE CAP
GNP NIACIN 100 MG TABLET
GNP FISH OIL SOFTGEL
COROMEGA OMEGA-3 SQUEEZE PACK
COROMEGA BRAIN & BODY PACKET
COROMEGA CHILD HIGH DHA PACKET
COROMEGA CHILD HIGH DHA PACKET
COROMEGA BRAIN & BODY GO-PAK
FISH OIL EXTRA STRENGTH SOFTGL
COQ-10 & FISH OIL SOFTGEL
FISH OIL 300 MG SOFTGEL
FISH OIL EXTRA STRENGTH SFTGEL
FISH OIL 1,000 MG EC SOFTGEL
HCA NIACIN 100 MG TABLET
HCA NIACIN 250 MG TABLET TR
HCA NIACIN 500 MG TABLET
PERFORMANCE MEASURE RULE:
Chronic Kidney Disease with LDL ≥ 130 – Consider Adding a Lipid Lowering Agent

DENOMINATOR

All of the following are correct:

1. If patient age ≥ 18 years
2. Presence of at least 1 LDL VALUE ≥ 130 in the past 6 months
3. One of the following is correct:
   a. CKD Stage 5 Validation is confirmed (see below)
   b. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 3 years

DENOMINATOR EXCLUSIONS

None

NUMERATOR

1. The denominator is true
2. One of the following is correct:
   a. Presence of at least 1 current refill for LIPID LOWERING AGENTS
   b. Presence of patient data confirming at least 1 LIPID LOWERING AGENTS in the past 6 months

VALIDATION RULES

CKD Stage 5 Validation

One of the following is correct:

1. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from EHR data
2. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from EHR data

This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.
3. Presence of at least 1 CKD STAGE 5 diagnosis in the past 12 months from disability data

4. Presence of at least 1 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months from disability data

5. Presence of at least 2 CKD STAGE 5 diagnosis in the past 12 months at least 3 months apart from claims data

6. Presence of at least 2 ESRD/DIALYSIS (ICD-9) diagnosis in the past 12 months at least 3 months apart from claims data

7. All of the following are correct:
   a. Presence of at least 2 CKD - NOS diagnosis in the past 12 months at least 3 months apart from claims data
   b. Presence of at least 1 result for creatinine clearance between 0.1 And 14 in the past
   c. Patient age ≥ 18 years

8. Presence of at least 2 DIALYSIS CHRONIC (CPT) procedure in the past 12 months

9. Presence of patient data confirming at least 1 PDD - DIALYSIS in the past 12 months

**CKD Stage 5 Validation Exclusion**

The following is correct:

1. Presence of at least 1 TRANSPLANT RENAL (CPT) procedure in the past 12 months

**Note:** A 3-month time window has been added to certain timeframes to account for the inherent delay in the acquisition of administrative claims data.

**Note:** A current refill is defined as a refill in which the total day supply of a drug plus a grace period of an additional 30 days extends into the end of the measurement window.